| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Idiopathic Pulmonary Fibrosis | 83 | 2026 | 690 | 19.620 |
Why?
|
| Mucin-5B | 51 | 2026 | 234 | 13.740 |
Why?
|
| Pulmonary Fibrosis | 56 | 2026 | 395 | 7.810 |
Why?
|
| Pregnancy Complications, Infectious | 21 | 2025 | 438 | 7.710 |
Why?
|
| Lipopolysaccharides | 60 | 2013 | 858 | 5.830 |
Why?
|
| Lung | 105 | 2026 | 4101 | 5.810 |
Why?
|
| Genetic Predisposition to Disease | 74 | 2026 | 2351 | 5.380 |
Why?
|
| Infectious Disease Transmission, Vertical | 17 | 2025 | 194 | 5.360 |
Why?
|
| Crohn Disease | 23 | 2026 | 258 | 5.290 |
Why?
|
| Lung Diseases, Interstitial | 33 | 2025 | 659 | 4.180 |
Why?
|
| Asthma | 42 | 2026 | 1795 | 3.560 |
Why?
|
| Polymorphism, Genetic | 31 | 2022 | 614 | 3.230 |
Why?
|
| Bleomycin | 15 | 2026 | 255 | 3.100 |
Why?
|
| Immunity, Innate | 30 | 2019 | 834 | 3.080 |
Why?
|
| Promoter Regions, Genetic | 27 | 2026 | 1244 | 2.980 |
Why?
|
| Rectal Fistula | 6 | 2022 | 27 | 2.920 |
Why?
|
| Toll-Like Receptor 4 | 38 | 2014 | 275 | 2.870 |
Why?
|
| Respiratory Mucosa | 20 | 2025 | 322 | 2.870 |
Why?
|
| Humans | 418 | 2026 | 145140 | 2.770 |
Why?
|
| Epigenesis, Genetic | 19 | 2022 | 672 | 2.750 |
Why?
|
| Placenta | 17 | 2024 | 784 | 2.740 |
Why?
|
| Genome-Wide Association Study | 34 | 2026 | 1376 | 2.710 |
Why?
|
| Membrane Glycoproteins | 21 | 2010 | 499 | 2.630 |
Why?
|
| Environmental Exposure | 18 | 2019 | 577 | 2.600 |
Why?
|
| Receptors, Cell Surface | 20 | 2015 | 372 | 2.580 |
Why?
|
| Pandemics | 12 | 2024 | 1703 | 2.540 |
Why?
|
| Dust | 23 | 2018 | 92 | 2.520 |
Why?
|
| Inflammatory Bowel Diseases | 19 | 2025 | 364 | 2.460 |
Why?
|
| Lung Diseases | 19 | 2018 | 780 | 2.440 |
Why?
|
| Coronavirus Infections | 6 | 2020 | 382 | 2.310 |
Why?
|
| Stillbirth | 9 | 2024 | 81 | 2.290 |
Why?
|
| DNA Methylation | 18 | 2022 | 667 | 2.260 |
Why?
|
| Polymorphism, Single Nucleotide | 37 | 2026 | 2136 | 2.220 |
Why?
|
| Pneumonia, Viral | 5 | 2020 | 388 | 2.210 |
Why?
|
| Genetic Variation | 18 | 2022 | 967 | 2.150 |
Why?
|
| Female | 233 | 2026 | 78636 | 2.060 |
Why?
|
| Endotoxins | 20 | 2013 | 217 | 2.000 |
Why?
|
| Animals | 160 | 2026 | 37952 | 2.000 |
Why?
|
| Bronchoalveolar Lavage Fluid | 49 | 2022 | 638 | 1.990 |
Why?
|
| Orthobunyavirus | 3 | 2025 | 8 | 1.970 |
Why?
|
| Alveolitis, Extrinsic Allergic | 3 | 2022 | 93 | 1.960 |
Why?
|
| Pregnancy | 41 | 2025 | 7182 | 1.960 |
Why?
|
| Mice | 116 | 2026 | 18303 | 1.950 |
Why?
|
| Bunyaviridae Infections | 3 | 2025 | 15 | 1.950 |
Why?
|
| Genomics | 14 | 2024 | 819 | 1.810 |
Why?
|
| Male | 241 | 2026 | 72664 | 1.800 |
Why?
|
| Bronchial Hyperreactivity | 19 | 2015 | 104 | 1.780 |
Why?
|
| Drosophila Proteins | 13 | 2002 | 212 | 1.730 |
Why?
|
| Colitis, Ulcerative | 8 | 2025 | 148 | 1.730 |
Why?
|
| Respiratory Tract Diseases | 12 | 2010 | 175 | 1.670 |
Why?
|
| Gene Expression Regulation | 25 | 2025 | 2588 | 1.650 |
Why?
|
| Pneumonia | 17 | 2012 | 635 | 1.590 |
Why?
|
| Infant, Newborn | 30 | 2025 | 6435 | 1.580 |
Why?
|
| Gene Expression | 24 | 2022 | 1474 | 1.580 |
Why?
|
| Toll-Like Receptors | 24 | 2018 | 193 | 1.570 |
Why?
|
| Zea mays | 13 | 2001 | 43 | 1.550 |
Why?
|
| Middle Aged | 147 | 2026 | 36126 | 1.510 |
Why?
|
| Gene Expression Profiling | 25 | 2024 | 1763 | 1.470 |
Why?
|
| Perinatal Death | 2 | 2022 | 26 | 1.460 |
Why?
|
| Quantitative Trait Loci | 10 | 2026 | 375 | 1.430 |
Why?
|
| Severe Acute Respiratory Syndrome | 3 | 2020 | 19 | 1.420 |
Why?
|
| Crime Victims | 4 | 2022 | 129 | 1.410 |
Why?
|
| Endoscopy, Gastrointestinal | 5 | 2023 | 237 | 1.410 |
Why?
|
| Betacoronavirus | 5 | 2020 | 287 | 1.390 |
Why?
|
| Genotype | 25 | 2025 | 1844 | 1.380 |
Why?
|
| Genetic Loci | 10 | 2026 | 258 | 1.350 |
Why?
|
| Transcriptome | 12 | 2024 | 1029 | 1.330 |
Why?
|
| Chorionic Villi | 2 | 2021 | 25 | 1.320 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 13 | 2023 | 919 | 1.310 |
Why?
|
| Interleukin-6 | 12 | 2022 | 775 | 1.310 |
Why?
|
| Phenotype | 29 | 2025 | 3138 | 1.300 |
Why?
|
| Lung Injury | 5 | 2026 | 241 | 1.290 |
Why?
|
| Cytokines | 33 | 2026 | 2048 | 1.290 |
Why?
|
| Tumor Necrosis Factor-alpha | 30 | 2024 | 1216 | 1.270 |
Why?
|
| Immunohistochemistry | 10 | 2021 | 1713 | 1.240 |
Why?
|
| Aged | 90 | 2026 | 26096 | 1.230 |
Why?
|
| Case-Control Studies | 32 | 2026 | 3616 | 1.210 |
Why?
|
| Hypersensitivity | 8 | 2026 | 254 | 1.210 |
Why?
|
| Mice, Inbred C57BL | 53 | 2026 | 5972 | 1.210 |
Why?
|
| Fluorescent Antibody Technique | 3 | 2021 | 365 | 1.200 |
Why?
|
| Lung Transplantation | 8 | 2025 | 329 | 1.150 |
Why?
|
| Allergens | 12 | 2024 | 386 | 1.130 |
Why?
|
| Biomarkers | 16 | 2026 | 4282 | 1.120 |
Why?
|
| Adult | 123 | 2026 | 40665 | 1.120 |
Why?
|
| Pouchitis | 4 | 2024 | 8 | 1.120 |
Why?
|
| Trophoblasts | 2 | 2021 | 218 | 1.110 |
Why?
|
| Pulmonary Surfactant-Associated Protein C | 4 | 2019 | 45 | 1.090 |
Why?
|
| Gain of Function Mutation | 4 | 2022 | 35 | 1.070 |
Why?
|
| Respiratory Hypersensitivity | 6 | 2018 | 65 | 1.070 |
Why?
|
| Disease Models, Animal | 32 | 2026 | 4552 | 1.060 |
Why?
|
| Administration, Inhalation | 27 | 2013 | 571 | 1.050 |
Why?
|
| Risk Factors | 43 | 2026 | 10857 | 1.050 |
Why?
|
| Mucociliary Clearance | 2 | 2018 | 44 | 1.050 |
Why?
|
| Interpersonal Relations | 5 | 2022 | 397 | 1.040 |
Why?
|
| Signal Transduction | 27 | 2022 | 5208 | 0.960 |
Why?
|
| Precision Medicine | 6 | 2024 | 459 | 0.960 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 18 | 2016 | 749 | 0.950 |
Why?
|
| Zoonoses | 1 | 2026 | 37 | 0.950 |
Why?
|
| Colonic Pouches | 4 | 2021 | 14 | 0.940 |
Why?
|
| Pulmonary Alveoli | 7 | 2025 | 385 | 0.930 |
Why?
|
| RNA | 9 | 2022 | 910 | 0.920 |
Why?
|
| Smoking | 28 | 2022 | 1470 | 0.900 |
Why?
|
| Epithelium | 4 | 2022 | 310 | 0.900 |
Why?
|
| Skin Tests | 3 | 2024 | 94 | 0.890 |
Why?
|
| Neutrophils | 24 | 2012 | 1123 | 0.870 |
Why?
|
| Acetone | 1 | 2024 | 12 | 0.870 |
Why?
|
| Asbestos | 10 | 2012 | 36 | 0.860 |
Why?
|
| Pregnancy Outcome | 4 | 2020 | 500 | 0.840 |
Why?
|
| Mucus | 4 | 2019 | 75 | 0.840 |
Why?
|
| Eukaryotic Initiation Factor-2 | 1 | 2023 | 31 | 0.810 |
Why?
|
| Macrophages | 16 | 2020 | 1500 | 0.800 |
Why?
|
| Poxviridae Infections | 1 | 2023 | 1 | 0.790 |
Why?
|
| Orthopoxvirus | 1 | 2023 | 4 | 0.790 |
Why?
|
| Variola virus | 1 | 2023 | 3 | 0.790 |
Why?
|
| Mandibular Advancement | 2 | 2023 | 2 | 0.790 |
Why?
|
| Microcephaly | 1 | 2024 | 104 | 0.790 |
Why?
|
| Blood Proteins | 3 | 2025 | 238 | 0.790 |
Why?
|
| Bullying | 3 | 2021 | 44 | 0.790 |
Why?
|
| Intestinal Fistula | 3 | 2021 | 18 | 0.790 |
Why?
|
| Haptens | 2 | 2021 | 25 | 0.780 |
Why?
|
| Genome, Human | 6 | 2021 | 419 | 0.780 |
Why?
|
| Early Diagnosis | 3 | 2022 | 251 | 0.770 |
Why?
|
| Graft Rejection | 5 | 2007 | 518 | 0.770 |
Why?
|
| Fibroblasts | 8 | 2026 | 1022 | 0.770 |
Why?
|
| Coronavirus | 2 | 2020 | 47 | 0.770 |
Why?
|
| Milk, Human | 1 | 2025 | 174 | 0.770 |
Why?
|
| Inhalation Exposure | 5 | 2012 | 103 | 0.770 |
Why?
|
| Inflammation | 28 | 2025 | 2876 | 0.760 |
Why?
|
| Necrosis | 2 | 2021 | 243 | 0.760 |
Why?
|
| Proctocolectomy, Restorative | 3 | 2021 | 23 | 0.760 |
Why?
|
| RNA, Messenger | 21 | 2021 | 2803 | 0.750 |
Why?
|
| Saccharopolyspora | 1 | 2022 | 6 | 0.740 |
Why?
|
| Occupational Exposure | 10 | 2018 | 355 | 0.740 |
Why?
|
| Occupational Diseases | 10 | 2008 | 165 | 0.740 |
Why?
|
| Caenorhabditis elegans | 5 | 2013 | 326 | 0.740 |
Why?
|
| beta-Lactamases | 7 | 2025 | 53 | 0.740 |
Why?
|
| Edible Grain | 8 | 2003 | 47 | 0.730 |
Why?
|
| Sequence Analysis, DNA | 9 | 2023 | 776 | 0.730 |
Why?
|
| Intestinal Obstruction | 1 | 2023 | 55 | 0.730 |
Why?
|
| Mice, Inbred Strains | 15 | 2016 | 396 | 0.730 |
Why?
|
| Placenta Diseases | 2 | 2024 | 20 | 0.730 |
Why?
|
| Bronchioles | 2 | 2026 | 29 | 0.720 |
Why?
|
| Chorioamnionitis | 1 | 2022 | 50 | 0.710 |
Why?
|
| Adenomatous Polyposis Coli | 2 | 2021 | 40 | 0.700 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 2 | 2020 | 35 | 0.700 |
Why?
|
| Mutation | 17 | 2022 | 4071 | 0.690 |
Why?
|
| Retrospective Studies | 32 | 2026 | 17247 | 0.690 |
Why?
|
| Respiratory System | 7 | 2022 | 150 | 0.690 |
Why?
|
| Fetus | 7 | 2024 | 804 | 0.690 |
Why?
|
| Cellular Senescence | 3 | 2026 | 226 | 0.690 |
Why?
|
| Immunoassay | 2 | 2021 | 109 | 0.680 |
Why?
|
| Integrins | 1 | 2022 | 90 | 0.680 |
Why?
|
| Maternal Exposure | 4 | 2020 | 188 | 0.680 |
Why?
|
| Escherichia coli | 17 | 2025 | 834 | 0.680 |
Why?
|
| Airway Obstruction | 6 | 2000 | 153 | 0.670 |
Why?
|
| Breast Feeding | 1 | 2025 | 446 | 0.670 |
Why?
|
| Mice, Inbred C3H | 16 | 2010 | 254 | 0.670 |
Why?
|
| United States | 40 | 2025 | 16065 | 0.670 |
Why?
|
| Epithelial Cells | 6 | 2024 | 1127 | 0.660 |
Why?
|
| Mice, Knockout | 22 | 2025 | 3114 | 0.660 |
Why?
|
| Receptors, Immunologic | 3 | 2015 | 208 | 0.650 |
Why?
|
| Ozone | 6 | 2012 | 115 | 0.650 |
Why?
|
| Ventilator-Induced Lung Injury | 2 | 2019 | 61 | 0.650 |
Why?
|
| Pulmonary Surfactant-Associated Protein A | 4 | 2019 | 30 | 0.650 |
Why?
|
| Gastrointestinal Agents | 5 | 2021 | 65 | 0.640 |
Why?
|
| Pathology, Molecular | 1 | 2020 | 25 | 0.640 |
Why?
|
| Digestive System Surgical Procedures | 2 | 2021 | 112 | 0.640 |
Why?
|
| Placental Insufficiency | 1 | 2022 | 126 | 0.640 |
Why?
|
| Neonatology | 1 | 2021 | 32 | 0.640 |
Why?
|
| Physicians | 3 | 2021 | 954 | 0.630 |
Why?
|
| Respiratory Function Tests | 17 | 2021 | 543 | 0.630 |
Why?
|
| Fibrosis | 10 | 2023 | 554 | 0.630 |
Why?
|
| Depression | 6 | 2022 | 1537 | 0.620 |
Why?
|
| Sleep Apnea, Obstructive | 2 | 2023 | 302 | 0.620 |
Why?
|
| Anti-Bacterial Agents | 13 | 2025 | 1922 | 0.610 |
Why?
|
| Nasal Mucosa | 3 | 2017 | 112 | 0.610 |
Why?
|
| Pulmonary Surfactant-Associated Proteins | 1 | 2019 | 9 | 0.600 |
Why?
|
| Macrophages, Alveolar | 10 | 2009 | 373 | 0.600 |
Why?
|
| Tomography, X-Ray Computed | 25 | 2025 | 2767 | 0.590 |
Why?
|
| RNA, Long Noncoding | 1 | 2021 | 172 | 0.590 |
Why?
|
| Cysts | 2 | 2019 | 112 | 0.590 |
Why?
|
| Aspartic Acid | 2 | 2014 | 88 | 0.590 |
Why?
|
| Friends | 1 | 2019 | 56 | 0.590 |
Why?
|
| Telemedicine | 7 | 2025 | 956 | 0.580 |
Why?
|
| Risk Assessment | 12 | 2020 | 3740 | 0.580 |
Why?
|
| Metagenomics | 2 | 2011 | 149 | 0.580 |
Why?
|
| Health Care Costs | 3 | 2022 | 425 | 0.580 |
Why?
|
| Orthomyxoviridae Infections | 1 | 2019 | 71 | 0.570 |
Why?
|
| Career Choice | 1 | 2021 | 234 | 0.570 |
Why?
|
| Fibrin | 3 | 2025 | 84 | 0.570 |
Why?
|
| Biomedical Research | 5 | 2024 | 717 | 0.560 |
Why?
|
| Matrix Metalloproteinase 7 | 2 | 2021 | 25 | 0.560 |
Why?
|
| Alpha-Globulins | 3 | 2009 | 20 | 0.560 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2021 | 992 | 0.560 |
Why?
|
| Cohort Studies | 24 | 2025 | 5988 | 0.560 |
Why?
|
| Social Identification | 1 | 2019 | 71 | 0.560 |
Why?
|
| Prenatal Exposure Delayed Effects | 4 | 2018 | 650 | 0.550 |
Why?
|
| Glycine | 2 | 2014 | 186 | 0.550 |
Why?
|
| Paraquat | 1 | 2018 | 13 | 0.540 |
Why?
|
| Serum Amyloid A Protein | 1 | 2018 | 32 | 0.540 |
Why?
|
| Disease | 3 | 2011 | 96 | 0.540 |
Why?
|
| Constriction, Pathologic | 6 | 2023 | 248 | 0.540 |
Why?
|
| Serologic Tests | 1 | 2018 | 54 | 0.540 |
Why?
|
| Lipopolysaccharide Receptors | 4 | 2007 | 88 | 0.540 |
Why?
|
| Research Design | 4 | 2020 | 1132 | 0.540 |
Why?
|
| Herbicides | 1 | 2018 | 27 | 0.540 |
Why?
|
| Patient Acceptance of Health Care | 3 | 2022 | 881 | 0.530 |
Why?
|
| Public Health | 4 | 2026 | 571 | 0.530 |
Why?
|
| Interferon-gamma | 8 | 2007 | 784 | 0.530 |
Why?
|
| Desmoplakins | 2 | 2022 | 24 | 0.530 |
Why?
|
| Adolescent Behavior | 2 | 2021 | 494 | 0.530 |
Why?
|
| CpG Islands | 6 | 2025 | 161 | 0.530 |
Why?
|
| Vital Capacity | 19 | 2015 | 292 | 0.520 |
Why?
|
| Peer Group | 5 | 2021 | 252 | 0.520 |
Why?
|
| Animal Husbandry | 6 | 2021 | 33 | 0.510 |
Why?
|
| Treatment Outcome | 18 | 2025 | 11741 | 0.510 |
Why?
|
| Endoscopy | 5 | 2023 | 317 | 0.510 |
Why?
|
| Immunosorbent Techniques | 1 | 2017 | 18 | 0.510 |
Why?
|
| Neutrophil Infiltration | 4 | 2012 | 104 | 0.510 |
Why?
|
| Complement C3 | 1 | 2018 | 185 | 0.500 |
Why?
|
| Phosphopeptides | 1 | 2017 | 19 | 0.500 |
Why?
|
| Patient Outcome Assessment | 1 | 2018 | 130 | 0.500 |
Why?
|
| Air Pollutants, Occupational | 4 | 2009 | 41 | 0.500 |
Why?
|
| Shock, Septic | 4 | 2011 | 227 | 0.490 |
Why?
|
| Telomere | 6 | 2024 | 287 | 0.490 |
Why?
|
| Horses | 1 | 2018 | 224 | 0.490 |
Why?
|
| Aged, 80 and over | 23 | 2024 | 8318 | 0.490 |
Why?
|
| Alleles | 9 | 2017 | 888 | 0.480 |
Why?
|
| Adolescent | 36 | 2026 | 22479 | 0.480 |
Why?
|
| Forced Expiratory Volume | 20 | 2025 | 450 | 0.480 |
Why?
|
| HLA-DQ beta-Chains | 1 | 2016 | 58 | 0.480 |
Why?
|
| Host-Pathogen Interactions | 1 | 2019 | 361 | 0.470 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 3 | 2026 | 239 | 0.470 |
Why?
|
| Electronic Nicotine Delivery Systems | 1 | 2018 | 108 | 0.470 |
Why?
|
| Methamphetamine | 1 | 2017 | 74 | 0.470 |
Why?
|
| Young Adult | 22 | 2026 | 14176 | 0.470 |
Why?
|
| Education, Medical, Graduate | 1 | 2021 | 562 | 0.470 |
Why?
|
| Point-of-Care Systems | 1 | 2018 | 188 | 0.460 |
Why?
|
| Population Surveillance | 3 | 2017 | 484 | 0.460 |
Why?
|
| HLA-DRB1 Chains | 1 | 2016 | 110 | 0.460 |
Why?
|
| Environmental Health | 2 | 2006 | 40 | 0.450 |
Why?
|
| Sequence Analysis, RNA | 3 | 2019 | 442 | 0.450 |
Why?
|
| China | 3 | 2020 | 269 | 0.450 |
Why?
|
| Idiopathic Interstitial Pneumonias | 4 | 2019 | 44 | 0.440 |
Why?
|
| Mothers | 4 | 2022 | 764 | 0.440 |
Why?
|
| Scleroderma, Systemic | 2 | 2013 | 123 | 0.440 |
Why?
|
| Prospective Studies | 27 | 2025 | 8035 | 0.440 |
Why?
|
| Urban Population | 3 | 2015 | 492 | 0.440 |
Why?
|
| Bronchial Provocation Tests | 8 | 2011 | 47 | 0.430 |
Why?
|
| Polymerase Chain Reaction | 13 | 2016 | 1039 | 0.430 |
Why?
|
| Monkeypox virus | 3 | 2023 | 23 | 0.430 |
Why?
|
| Disease Outbreaks | 7 | 2025 | 419 | 0.430 |
Why?
|
| Arthritis, Rheumatoid | 6 | 2022 | 1174 | 0.420 |
Why?
|
| Th2 Cells | 4 | 2012 | 175 | 0.420 |
Why?
|
| GTPase-Activating Proteins | 4 | 2023 | 81 | 0.420 |
Why?
|
| Whole Genome Sequencing | 4 | 2025 | 177 | 0.420 |
Why?
|
| Cilia | 3 | 2022 | 173 | 0.410 |
Why?
|
| Gram-Negative Bacterial Infections | 3 | 2018 | 49 | 0.410 |
Why?
|
| Intercellular Adhesion Molecule-1 | 3 | 2003 | 132 | 0.410 |
Why?
|
| Chronic Disease | 12 | 2024 | 1806 | 0.410 |
Why?
|
| Immunoglobulin E | 8 | 2015 | 315 | 0.410 |
Why?
|
| Inhalation | 3 | 2008 | 29 | 0.410 |
Why?
|
| Environment | 2 | 2006 | 293 | 0.400 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2015 | 573 | 0.400 |
Why?
|
| Endoplasmic Reticulum Stress | 2 | 2026 | 118 | 0.400 |
Why?
|
| Carbapenems | 3 | 2025 | 27 | 0.400 |
Why?
|
| Chromosomes, Mammalian | 2 | 2011 | 28 | 0.400 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 2013 | 21 | 0.390 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2015 | 227 | 0.390 |
Why?
|
| Quality of Life | 10 | 2022 | 3194 | 0.390 |
Why?
|
| Interleukin-10 | 4 | 2006 | 309 | 0.390 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 6 | 2024 | 103 | 0.380 |
Why?
|
| Text Messaging | 4 | 2019 | 182 | 0.380 |
Why?
|
| Health Status | 5 | 2011 | 832 | 0.380 |
Why?
|
| National Institutes of Health (U.S.) | 4 | 2006 | 147 | 0.380 |
Why?
|
| Fibrinolysis | 2 | 2025 | 164 | 0.380 |
Why?
|
| Hospitalization | 7 | 2025 | 2458 | 0.380 |
Why?
|
| Prevalence | 14 | 2022 | 2855 | 0.370 |
Why?
|
| Clinical Competence | 1 | 2021 | 1240 | 0.370 |
Why?
|
| Aggression | 3 | 2021 | 178 | 0.370 |
Why?
|
| Diffusion of Innovation | 2 | 2018 | 96 | 0.370 |
Why?
|
| Fetal Growth Retardation | 2 | 2020 | 592 | 0.370 |
Why?
|
| Immune Tolerance | 3 | 2013 | 385 | 0.370 |
Why?
|
| PPAR gamma | 1 | 2013 | 178 | 0.370 |
Why?
|
| Sarcoidosis | 3 | 2013 | 163 | 0.370 |
Why?
|
| Severity of Illness Index | 10 | 2026 | 2928 | 0.370 |
Why?
|
| Disease Progression | 14 | 2025 | 2857 | 0.370 |
Why?
|
| Pulmonary Emphysema | 3 | 2025 | 277 | 0.360 |
Why?
|
| Hyaluronic Acid | 3 | 2009 | 225 | 0.360 |
Why?
|
| Respiratory Mechanics | 4 | 1994 | 74 | 0.360 |
Why?
|
| Pleural Diseases | 5 | 1993 | 23 | 0.360 |
Why?
|
| Enterobacteriaceae Infections | 4 | 2021 | 42 | 0.360 |
Why?
|
| Telomere Homeostasis | 3 | 2024 | 33 | 0.360 |
Why?
|
| Species Specificity | 9 | 2017 | 545 | 0.360 |
Why?
|
| Asbestosis | 9 | 1994 | 13 | 0.360 |
Why?
|
| DNA | 5 | 2022 | 1433 | 0.360 |
Why?
|
| Survival Analysis | 6 | 2020 | 1371 | 0.350 |
Why?
|
| Iran | 2 | 2023 | 44 | 0.350 |
Why?
|
| Lipid A | 2 | 2005 | 27 | 0.350 |
Why?
|
| Longitudinal Studies | 10 | 2021 | 2949 | 0.350 |
Why?
|
| Enterobacteriaceae | 5 | 2021 | 44 | 0.350 |
Why?
|
| Persian Gulf Syndrome | 5 | 2004 | 18 | 0.350 |
Why?
|
| Infant | 12 | 2026 | 10060 | 0.350 |
Why?
|
| RNA Interference | 8 | 2016 | 474 | 0.350 |
Why?
|
| Warfare | 3 | 2002 | 98 | 0.340 |
Why?
|
| Hypoxia | 2 | 2022 | 1197 | 0.340 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2011 | 59 | 0.330 |
Why?
|
| Science | 1 | 2012 | 55 | 0.330 |
Why?
|
| Enterococcus faecium | 2 | 2022 | 22 | 0.330 |
Why?
|
| Dilatation | 2 | 2023 | 71 | 0.330 |
Why?
|
| Cross Infection | 4 | 2020 | 260 | 0.330 |
Why?
|
| Agricultural Workers' Diseases | 3 | 1996 | 29 | 0.330 |
Why?
|
| Cell Line | 12 | 2021 | 2821 | 0.330 |
Why?
|
| Bone Marrow Transplantation | 4 | 2009 | 297 | 0.330 |
Why?
|
| Proteome | 3 | 2025 | 512 | 0.320 |
Why?
|
| Gram-Positive Bacterial Infections | 2 | 2022 | 71 | 0.320 |
Why?
|
| Methacholine Chloride | 10 | 2015 | 51 | 0.320 |
Why?
|
| Mucin 5AC | 4 | 2015 | 71 | 0.320 |
Why?
|
| Colectomy | 2 | 2021 | 106 | 0.320 |
Why?
|
| Fucosyltransferases | 2 | 2022 | 33 | 0.310 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2012 | 417 | 0.310 |
Why?
|
| Hematopoietic Stem Cells | 4 | 2020 | 418 | 0.310 |
Why?
|
| Medicine | 1 | 2012 | 125 | 0.310 |
Why?
|
| Colon | 2 | 2024 | 308 | 0.310 |
Why?
|
| ErbB Receptors | 3 | 2021 | 635 | 0.310 |
Why?
|
| Lung Diseases, Obstructive | 3 | 2001 | 43 | 0.310 |
Why?
|
| Disease Susceptibility | 3 | 2013 | 343 | 0.310 |
Why?
|
| Hyaluronan Receptors | 3 | 2009 | 104 | 0.310 |
Why?
|
| Air Pollutants | 4 | 2013 | 405 | 0.310 |
Why?
|
| Mice, Transgenic | 7 | 2019 | 2185 | 0.300 |
Why?
|
| Toll-Like Receptor 2 | 6 | 2013 | 125 | 0.300 |
Why?
|
| Germ Cells | 1 | 2009 | 65 | 0.300 |
Why?
|
| Global Health | 2 | 2026 | 403 | 0.300 |
Why?
|
| Receptors, Interleukin-1 Type I | 2 | 2007 | 25 | 0.300 |
Why?
|
| Karyotyping | 2 | 2008 | 105 | 0.300 |
Why?
|
| Regression Analysis | 8 | 2023 | 998 | 0.290 |
Why?
|
| Recurrence | 5 | 2021 | 1134 | 0.290 |
Why?
|
| Multivariate Analysis | 11 | 2019 | 1546 | 0.290 |
Why?
|
| Interleukin-1 | 9 | 2003 | 961 | 0.290 |
Why?
|
| Kidney Transplantation | 2 | 2025 | 710 | 0.290 |
Why?
|
| Pleura | 4 | 1994 | 28 | 0.280 |
Why?
|
| Chromosome Mapping | 6 | 2011 | 504 | 0.280 |
Why?
|
| Caenorhabditis elegans Proteins | 4 | 2013 | 207 | 0.280 |
Why?
|
| Housing, Animal | 1 | 2009 | 46 | 0.280 |
Why?
|
| Mice, Inbred BALB C | 9 | 2015 | 1261 | 0.280 |
Why?
|
| Flour | 1 | 2008 | 6 | 0.280 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 6 | 2020 | 456 | 0.280 |
Why?
|
| Lung Diseases, Fungal | 1 | 2008 | 12 | 0.280 |
Why?
|
| Base Sequence | 7 | 2017 | 2168 | 0.280 |
Why?
|
| Angiogenesis Inducing Agents | 1 | 2008 | 25 | 0.280 |
Why?
|
| Aspergillosis | 1 | 2008 | 24 | 0.280 |
Why?
|
| Fecal Microbiota Transplantation | 2 | 2026 | 27 | 0.280 |
Why?
|
| Gene Frequency | 8 | 2023 | 484 | 0.280 |
Why?
|
| Plasminogen | 1 | 2008 | 27 | 0.270 |
Why?
|
| Bronchiolitis Obliterans | 2 | 2006 | 61 | 0.270 |
Why?
|
| DNA, Bacterial | 3 | 2014 | 320 | 0.270 |
Why?
|
| MicroRNAs | 4 | 2023 | 686 | 0.270 |
Why?
|
| Bacterial Proteins | 4 | 2025 | 962 | 0.270 |
Why?
|
| Dose-Response Relationship, Drug | 7 | 2019 | 2026 | 0.270 |
Why?
|
| Total Lung Capacity | 9 | 2015 | 29 | 0.270 |
Why?
|
| Follow-Up Studies | 16 | 2019 | 5411 | 0.270 |
Why?
|
| Genes | 2 | 2006 | 226 | 0.270 |
Why?
|
| Japan | 2 | 2026 | 148 | 0.270 |
Why?
|
| Infant, Premature | 2 | 2023 | 619 | 0.270 |
Why?
|
| Longevity | 1 | 2009 | 177 | 0.270 |
Why?
|
| Ovalbumin | 8 | 2015 | 194 | 0.270 |
Why?
|
| Transplantation Immunology | 2 | 2005 | 29 | 0.270 |
Why?
|
| Pregnancy Complications | 1 | 2013 | 600 | 0.270 |
Why?
|
| Anti-Inflammatory Agents | 3 | 2021 | 477 | 0.270 |
Why?
|
| Spirometry | 9 | 2025 | 233 | 0.270 |
Why?
|
| Genetic Markers | 5 | 2022 | 333 | 0.270 |
Why?
|
| Graft Survival | 3 | 2007 | 517 | 0.260 |
Why?
|
| Histones | 3 | 2022 | 665 | 0.260 |
Why?
|
| Airway Resistance | 4 | 2011 | 38 | 0.260 |
Why?
|
| Apoptosis | 5 | 2026 | 2434 | 0.260 |
Why?
|
| Complement Inactivator Proteins | 1 | 2007 | 39 | 0.260 |
Why?
|
| Bronchi | 5 | 2005 | 263 | 0.260 |
Why?
|
| Leukocyte Count | 7 | 2009 | 316 | 0.260 |
Why?
|
| Streptococcus | 1 | 2007 | 29 | 0.260 |
Why?
|
| Intestinal Mucosa | 4 | 2024 | 674 | 0.260 |
Why?
|
| Otitis Media | 3 | 2019 | 181 | 0.260 |
Why?
|
| Veterans | 6 | 2004 | 1625 | 0.260 |
Why?
|
| Complement System Proteins | 2 | 2007 | 313 | 0.260 |
Why?
|
| Bronchoconstriction | 4 | 2011 | 29 | 0.260 |
Why?
|
| Child | 19 | 2026 | 22670 | 0.250 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 2 | 2026 | 280 | 0.250 |
Why?
|
| Dyspnea | 6 | 2023 | 250 | 0.250 |
Why?
|
| Telomerase | 2 | 2019 | 246 | 0.250 |
Why?
|
| Immunosuppressive Agents | 6 | 2020 | 837 | 0.250 |
Why?
|
| Mutation, Missense | 4 | 2002 | 335 | 0.250 |
Why?
|
| Macrophages, Peritoneal | 1 | 2007 | 89 | 0.250 |
Why?
|
| Time Factors | 20 | 2019 | 7107 | 0.250 |
Why?
|
| Cyclophosphamide | 3 | 2024 | 266 | 0.250 |
Why?
|
| Leukocytes | 3 | 2006 | 296 | 0.250 |
Why?
|
| Age Factors | 11 | 2019 | 3338 | 0.250 |
Why?
|
| Neovascularization, Pathologic | 1 | 2008 | 285 | 0.250 |
Why?
|
| Proteomics | 5 | 2025 | 1185 | 0.240 |
Why?
|
| Logistic Models | 8 | 2019 | 2133 | 0.240 |
Why?
|
| Prednisone | 3 | 2024 | 221 | 0.240 |
Why?
|
| Toll-Like Receptor 5 | 1 | 2026 | 18 | 0.240 |
Why?
|
| Proportional Hazards Models | 9 | 2019 | 1325 | 0.240 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 5 | 2013 | 847 | 0.240 |
Why?
|
| Vaccination | 3 | 2024 | 1423 | 0.240 |
Why?
|
| Escherichia coli Infections | 2 | 2020 | 125 | 0.240 |
Why?
|
| Toxicology | 1 | 2006 | 49 | 0.230 |
Why?
|
| Clinical Medicine | 1 | 2006 | 26 | 0.230 |
Why?
|
| Arteriosclerosis | 2 | 2004 | 83 | 0.230 |
Why?
|
| Citrobacter | 1 | 2025 | 3 | 0.230 |
Why?
|
| DNA Helicases | 2 | 2019 | 136 | 0.230 |
Why?
|
| Receptors, CCR5 | 1 | 2006 | 60 | 0.230 |
Why?
|
| Nuclear Receptor Subfamily 1, Group F, Member 3 | 1 | 2025 | 14 | 0.230 |
Why?
|
| Drug Resistance, Bacterial | 2 | 2021 | 185 | 0.230 |
Why?
|
| Self Care | 2 | 2019 | 388 | 0.230 |
Why?
|
| Genetic Linkage | 4 | 2011 | 271 | 0.230 |
Why?
|
| Reproducibility of Results | 10 | 2018 | 3410 | 0.230 |
Why?
|
| Sepsis | 3 | 2010 | 662 | 0.230 |
Why?
|
| Transforming Growth Factor beta1 | 6 | 2007 | 176 | 0.230 |
Why?
|
| Acinetobacter baumannii | 1 | 2025 | 26 | 0.230 |
Why?
|
| Hyperoxia | 1 | 2006 | 96 | 0.230 |
Why?
|
| Laser Capture Microdissection | 1 | 2025 | 29 | 0.230 |
Why?
|
| Tobacco Use | 2 | 2023 | 62 | 0.220 |
Why?
|
| Registries | 4 | 2023 | 2401 | 0.220 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2019 | 530 | 0.220 |
Why?
|
| Ligands | 3 | 2022 | 664 | 0.220 |
Why?
|
| Complement Activation | 2 | 2007 | 399 | 0.220 |
Why?
|
| Organizational Objectives | 1 | 2005 | 67 | 0.220 |
Why?
|
| Inflammation Mediators | 5 | 2019 | 506 | 0.220 |
Why?
|
| Microbial Sensitivity Tests | 5 | 2025 | 363 | 0.220 |
Why?
|
| Colorado | 3 | 2020 | 4538 | 0.220 |
Why?
|
| Mice, Inbred DBA | 4 | 2008 | 182 | 0.220 |
Why?
|
| Markov Chains | 1 | 2025 | 129 | 0.220 |
Why?
|
| Linkage Disequilibrium | 3 | 2016 | 250 | 0.220 |
Why?
|
| Sulfonamides | 2 | 2026 | 583 | 0.220 |
Why?
|
| Streptococcal Infections | 1 | 2007 | 171 | 0.220 |
Why?
|
| Dual Oxidases | 1 | 2024 | 4 | 0.220 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2020 | 623 | 0.210 |
Why?
|
| Communicable Diseases, Emerging | 1 | 2025 | 39 | 0.210 |
Why?
|
| Image Processing, Computer-Assisted | 3 | 2021 | 777 | 0.210 |
Why?
|
| Congresses as Topic | 3 | 2018 | 223 | 0.210 |
Why?
|
| Gram-Negative Bacteria | 3 | 2018 | 80 | 0.210 |
Why?
|
| Acute-Phase Proteins | 1 | 2004 | 66 | 0.210 |
Why?
|
| Patient Education as Topic | 2 | 2021 | 775 | 0.210 |
Why?
|
| Culture Media | 4 | 2018 | 161 | 0.210 |
Why?
|
| Dysbiosis | 1 | 2026 | 187 | 0.210 |
Why?
|
| Quantitative Trait, Heritable | 1 | 2005 | 113 | 0.210 |
Why?
|
| Exome | 2 | 2023 | 227 | 0.210 |
Why?
|
| Environmental Illness | 1 | 2004 | 3 | 0.210 |
Why?
|
| Incidence | 2 | 2023 | 2915 | 0.210 |
Why?
|
| Klebsiella pneumoniae | 3 | 2020 | 47 | 0.210 |
Why?
|
| Dietary Supplements | 1 | 2008 | 582 | 0.210 |
Why?
|
| Cell Movement | 2 | 2007 | 959 | 0.210 |
Why?
|
| Lipocalin-2 | 1 | 2024 | 80 | 0.210 |
Why?
|
| Vancomycin Resistance | 2 | 2022 | 16 | 0.210 |
Why?
|
| Extracellular Matrix | 3 | 2014 | 561 | 0.200 |
Why?
|
| Lyme Disease | 1 | 2024 | 58 | 0.200 |
Why?
|
| Interleukin-8 | 7 | 2009 | 269 | 0.200 |
Why?
|
| Virulence Factors | 1 | 2025 | 174 | 0.200 |
Why?
|
| Vincristine | 1 | 2024 | 140 | 0.200 |
Why?
|
| Epigenomics | 2 | 2017 | 112 | 0.200 |
Why?
|
| Lung Neoplasms | 3 | 2025 | 2662 | 0.200 |
Why?
|
| Interleukin-13 | 4 | 2019 | 146 | 0.200 |
Why?
|
| Pneumonia, Bacterial | 1 | 2004 | 113 | 0.200 |
Why?
|
| Nigeria | 1 | 2023 | 24 | 0.200 |
Why?
|
| Ileum | 1 | 2024 | 112 | 0.200 |
Why?
|
| Chagas Cardiomyopathy | 2 | 2015 | 27 | 0.200 |
Why?
|
| Insurance | 1 | 2023 | 14 | 0.200 |
Why?
|
| Antibodies, Bispecific | 1 | 2024 | 68 | 0.200 |
Why?
|
| Vaccinia virus | 1 | 2023 | 35 | 0.200 |
Why?
|
| Transcription, Genetic | 4 | 2013 | 1454 | 0.200 |
Why?
|
| Rituximab | 1 | 2024 | 210 | 0.200 |
Why?
|
| Microbiota | 4 | 2026 | 729 | 0.190 |
Why?
|
| Dogs | 1 | 2024 | 438 | 0.190 |
Why?
|
| Iowa | 7 | 2004 | 31 | 0.190 |
Why?
|
| Occlusal Splints | 1 | 2023 | 2 | 0.190 |
Why?
|
| Biomarkers, Tumor | 3 | 2024 | 1320 | 0.190 |
Why?
|
| Acute Disease | 6 | 2021 | 1035 | 0.190 |
Why?
|
| Eukaryotic Initiation Factor-2B | 1 | 2023 | 6 | 0.190 |
Why?
|
| Carrier State | 2 | 2021 | 78 | 0.190 |
Why?
|
| Alveolar Epithelial Cells | 3 | 2019 | 120 | 0.190 |
Why?
|
| Dermatitis, Atopic | 2 | 2022 | 322 | 0.190 |
Why?
|
| Lordosis | 1 | 2023 | 16 | 0.190 |
Why?
|
| Drug Repositioning | 1 | 2023 | 39 | 0.190 |
Why?
|
| Hypersensitivity, Immediate | 2 | 2008 | 41 | 0.190 |
Why?
|
| Transcription Factors | 4 | 2021 | 1731 | 0.190 |
Why?
|
| Reperfusion Injury | 1 | 2025 | 292 | 0.190 |
Why?
|
| Bacteroides fragilis | 1 | 2002 | 14 | 0.190 |
Why?
|
| Hemorrhagic Fevers, Viral | 1 | 2022 | 16 | 0.190 |
Why?
|
| Mucins | 3 | 2019 | 75 | 0.190 |
Why?
|
| Pedigree | 7 | 2019 | 515 | 0.190 |
Why?
|
| Survival Rate | 8 | 2019 | 2087 | 0.190 |
Why?
|
| CD11b Antigen | 1 | 2002 | 60 | 0.180 |
Why?
|
| Piperidines | 1 | 2024 | 220 | 0.180 |
Why?
|
| Silicosis | 1 | 2023 | 30 | 0.180 |
Why?
|
| Obstetric Labor, Premature | 1 | 2002 | 39 | 0.180 |
Why?
|
| Exanthema | 1 | 2023 | 86 | 0.180 |
Why?
|
| Social Adjustment | 1 | 2022 | 64 | 0.180 |
Why?
|
| Indoles | 1 | 2026 | 507 | 0.180 |
Why?
|
| ROC Curve | 3 | 2019 | 617 | 0.180 |
Why?
|
| DNA Mutational Analysis | 6 | 2017 | 407 | 0.180 |
Why?
|
| Blotting, Western | 4 | 2013 | 1177 | 0.180 |
Why?
|
| Chemokine CXCL2 | 5 | 2001 | 41 | 0.180 |
Why?
|
| Bacterial Infections | 6 | 2013 | 246 | 0.180 |
Why?
|
| Vancomycin-Resistant Enterococci | 1 | 2022 | 9 | 0.180 |
Why?
|
| Gene Regulatory Networks | 2 | 2016 | 317 | 0.180 |
Why?
|
| Organ Transplantation | 1 | 2025 | 250 | 0.180 |
Why?
|
| Double-Blind Method | 5 | 2021 | 2057 | 0.180 |
Why?
|
| Doxorubicin | 1 | 2024 | 396 | 0.180 |
Why?
|
| Epidemiologic Methods | 1 | 2002 | 91 | 0.180 |
Why?
|
| Internationality | 1 | 2022 | 156 | 0.180 |
Why?
|
| Abscess | 1 | 2022 | 77 | 0.180 |
Why?
|
| Fetal Death | 1 | 2022 | 57 | 0.180 |
Why?
|
| A549 Cells | 2 | 2021 | 74 | 0.180 |
Why?
|
| Adaptor Proteins, Signal Transducing | 3 | 2021 | 425 | 0.180 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2024 | 193 | 0.180 |
Why?
|
| Monokines | 5 | 2000 | 21 | 0.170 |
Why?
|
| Peptide Hydrolases | 1 | 2022 | 105 | 0.170 |
Why?
|
| Educational Status | 1 | 2024 | 465 | 0.170 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2017 | 968 | 0.170 |
Why?
|
| Tyrphostins | 1 | 2021 | 18 | 0.170 |
Why?
|
| Cross-Sectional Studies | 10 | 2020 | 5886 | 0.170 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2001 | 75 | 0.170 |
Why?
|
| Amphiregulin | 1 | 2021 | 27 | 0.170 |
Why?
|
| Bacteremia | 3 | 2013 | 222 | 0.170 |
Why?
|
| Health Surveys | 2 | 2009 | 517 | 0.170 |
Why?
|
| Eosinophils | 5 | 2015 | 316 | 0.170 |
Why?
|
| Immunity | 1 | 2022 | 140 | 0.170 |
Why?
|
| Mendelian Randomization Analysis | 2 | 2022 | 54 | 0.170 |
Why?
|
| Receptors, Interleukin-1 | 4 | 2010 | 211 | 0.170 |
Why?
|
| Forecasting | 2 | 2020 | 388 | 0.170 |
Why?
|
| Biophysical Phenomena | 1 | 2021 | 67 | 0.170 |
Why?
|
| E2F1 Transcription Factor | 2 | 2012 | 68 | 0.170 |
Why?
|
| Multifactorial Inheritance | 1 | 2022 | 190 | 0.170 |
Why?
|
| Keratin-5 | 1 | 2021 | 44 | 0.170 |
Why?
|
| Prognosis | 9 | 2019 | 4310 | 0.170 |
Why?
|
| Brain-Computer Interfaces | 1 | 2021 | 12 | 0.170 |
Why?
|
| Abruptio Placentae | 1 | 2020 | 6 | 0.170 |
Why?
|
| Fetal Mortality | 1 | 2020 | 4 | 0.170 |
Why?
|
| Phagocytosis | 3 | 2013 | 296 | 0.160 |
Why?
|
| Tennessee | 1 | 2020 | 57 | 0.160 |
Why?
|
| Office Visits | 1 | 2021 | 92 | 0.160 |
Why?
|
| Isoenzymes | 1 | 2001 | 294 | 0.160 |
Why?
|
| Chemokines | 4 | 2012 | 217 | 0.160 |
Why?
|
| Electric Impedance | 1 | 2021 | 108 | 0.160 |
Why?
|
| Swine | 5 | 2014 | 822 | 0.160 |
Why?
|
| Cell Communication | 1 | 2022 | 328 | 0.160 |
Why?
|
| Home Childbirth | 1 | 2020 | 5 | 0.160 |
Why?
|
| Antirheumatic Agents | 2 | 2021 | 307 | 0.160 |
Why?
|
| Genetic Association Studies | 4 | 2015 | 367 | 0.160 |
Why?
|
| Doulas | 1 | 2020 | 4 | 0.160 |
Why?
|
| Pyrimidines | 1 | 2024 | 530 | 0.160 |
Why?
|
| Viruses | 1 | 2022 | 164 | 0.160 |
Why?
|
| Staining and Labeling | 1 | 2021 | 153 | 0.160 |
Why?
|
| Odds Ratio | 5 | 2018 | 1082 | 0.160 |
Why?
|
| Thyroid Neoplasms | 1 | 2024 | 350 | 0.160 |
Why?
|
| Carrier Proteins | 1 | 2004 | 728 | 0.160 |
Why?
|
| Human papillomavirus 18 | 1 | 2020 | 12 | 0.160 |
Why?
|
| Ferrosoferric Oxide | 1 | 2020 | 25 | 0.160 |
Why?
|
| Klebsiella Infections | 1 | 2020 | 26 | 0.160 |
Why?
|
| Cells, Cultured | 10 | 2018 | 4142 | 0.160 |
Why?
|
| Transforming Growth Factor beta | 4 | 2003 | 474 | 0.160 |
Why?
|
| Receptor for Advanced Glycation End Products | 2 | 2017 | 33 | 0.160 |
Why?
|
| Vaccines, DNA | 1 | 2020 | 32 | 0.160 |
Why?
|
| Farmers | 1 | 2021 | 71 | 0.160 |
Why?
|
| Human papillomavirus 16 | 1 | 2020 | 27 | 0.150 |
Why?
|
| Molecular Sequence Data | 8 | 2011 | 2881 | 0.150 |
Why?
|
| Gastroenterologists | 1 | 2020 | 21 | 0.150 |
Why?
|
| Bronchoalveolar Lavage | 3 | 2014 | 89 | 0.150 |
Why?
|
| Keratin-15 | 1 | 2019 | 16 | 0.150 |
Why?
|
| Binding Sites | 3 | 2021 | 1309 | 0.150 |
Why?
|
| Quinazolines | 1 | 2021 | 266 | 0.150 |
Why?
|
| Peer Influence | 1 | 2019 | 14 | 0.150 |
Why?
|
| Diagnosis, Differential | 3 | 2025 | 1506 | 0.150 |
Why?
|
| Professional Autonomy | 1 | 2019 | 29 | 0.150 |
Why?
|
| Wound Healing | 2 | 2017 | 354 | 0.150 |
Why?
|
| Rectum | 1 | 2021 | 182 | 0.150 |
Why?
|
| Spinal Fusion | 1 | 2023 | 261 | 0.150 |
Why?
|
| Spleen | 3 | 2012 | 507 | 0.150 |
Why?
|
| Histoplasmosis | 1 | 2019 | 15 | 0.150 |
Why?
|
| Lymphocyte Subsets | 1 | 2019 | 77 | 0.150 |
Why?
|
| Interleukin-4 | 2 | 2015 | 207 | 0.150 |
Why?
|
| Colloids | 1 | 2019 | 59 | 0.150 |
Why?
|
| Hospital Medicine | 1 | 2021 | 97 | 0.150 |
Why?
|
| alpha-Macroglobulins | 1 | 2019 | 25 | 0.150 |
Why?
|
| Interferon-beta | 2 | 2011 | 92 | 0.150 |
Why?
|
| Proteins | 4 | 2015 | 1022 | 0.150 |
Why?
|
| Skin Diseases | 2 | 2018 | 152 | 0.150 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2020 | 3892 | 0.150 |
Why?
|
| ERG1 Potassium Channel | 1 | 2018 | 6 | 0.150 |
Why?
|
| Chromosomes | 3 | 2008 | 106 | 0.150 |
Why?
|
| Interleukin-5 Receptor alpha Subunit | 1 | 2018 | 6 | 0.140 |
Why?
|
| Delivery, Obstetric | 1 | 2020 | 160 | 0.140 |
Why?
|
| Expectorants | 1 | 2018 | 23 | 0.140 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2020 | 1742 | 0.140 |
Why?
|
| Gastrointestinal Contents | 1 | 1998 | 8 | 0.140 |
Why?
|
| Exoribonucleases | 1 | 2019 | 43 | 0.140 |
Why?
|
| Interleukin-12 | 1 | 1999 | 115 | 0.140 |
Why?
|
| Consensus | 4 | 2021 | 478 | 0.140 |
Why?
|
| Midwifery | 1 | 2020 | 65 | 0.140 |
Why?
|
| Pneumonia, Aspiration | 1 | 1998 | 16 | 0.140 |
Why?
|
| Colistin | 1 | 2018 | 10 | 0.140 |
Why?
|
| Mucous Membrane | 1 | 2019 | 128 | 0.140 |
Why?
|
| Viral Vaccines | 1 | 2020 | 107 | 0.140 |
Why?
|
| Adipokines | 1 | 2019 | 57 | 0.140 |
Why?
|
| Colonic Polyps | 1 | 2020 | 85 | 0.140 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2019 | 117 | 0.140 |
Why?
|
| Staphylococcal Infections | 2 | 2016 | 390 | 0.140 |
Why?
|
| Maternal Health Services | 1 | 2020 | 101 | 0.140 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2019 | 96 | 0.140 |
Why?
|
| Nasal Lavage Fluid | 2 | 2009 | 15 | 0.140 |
Why?
|
| Smoking Cessation | 2 | 2020 | 437 | 0.140 |
Why?
|
| Colitis | 1 | 2021 | 280 | 0.140 |
Why?
|
| Prenatal Nutritional Physiological Phenomena | 2 | 2008 | 55 | 0.140 |
Why?
|
| Chemoradiotherapy | 1 | 2020 | 239 | 0.140 |
Why?
|
| Liver Transplantation | 1 | 2025 | 826 | 0.140 |
Why?
|
| Sri Lanka | 1 | 2018 | 7 | 0.140 |
Why?
|
| Oligonucleotides | 1 | 1999 | 153 | 0.140 |
Why?
|
| Hedgehog Proteins | 3 | 2022 | 200 | 0.140 |
Why?
|
| Lymphocytes | 4 | 2008 | 376 | 0.140 |
Why?
|
| Rhodobacter sphaeroides | 1 | 1998 | 7 | 0.140 |
Why?
|
| Certolizumab Pegol | 1 | 2017 | 5 | 0.140 |
Why?
|
| Microscopy, Fluorescence | 3 | 2017 | 408 | 0.140 |
Why?
|
| Israel | 4 | 2021 | 46 | 0.140 |
Why?
|
| Biological Products | 2 | 2021 | 257 | 0.140 |
Why?
|
| Heterozygote | 6 | 2021 | 312 | 0.140 |
Why?
|
| Triamcinolone Acetonide | 1 | 1998 | 20 | 0.130 |
Why?
|
| Evidence-Based Practice | 1 | 2020 | 231 | 0.130 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2019 | 159 | 0.130 |
Why?
|
| Infant, Small for Gestational Age | 1 | 2019 | 118 | 0.130 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2020 | 288 | 0.130 |
Why?
|
| Particulate Matter | 3 | 2009 | 325 | 0.130 |
Why?
|
| Combined Modality Therapy | 2 | 2019 | 1264 | 0.130 |
Why?
|
| Adalimumab | 1 | 2018 | 55 | 0.130 |
Why?
|
| Intestines | 1 | 2021 | 354 | 0.130 |
Why?
|
| Macrophage Activation | 4 | 2011 | 181 | 0.130 |
Why?
|
| Telomere-Binding Proteins | 1 | 2019 | 119 | 0.130 |
Why?
|
| Safety | 1 | 2020 | 357 | 0.130 |
Why?
|
| RNA Polymerase II | 2 | 2021 | 350 | 0.130 |
Why?
|
| Point Mutation | 2 | 2000 | 239 | 0.130 |
Why?
|
| Practice Management, Medical | 1 | 2017 | 25 | 0.130 |
Why?
|
| Child, Preschool | 10 | 2026 | 11835 | 0.130 |
Why?
|
| Adenoma | 1 | 2020 | 218 | 0.130 |
Why?
|
| Betaine | 1 | 2018 | 67 | 0.130 |
Why?
|
| Adoptive Transfer | 3 | 2009 | 199 | 0.130 |
Why?
|
| Virus Replication | 1 | 2020 | 519 | 0.130 |
Why?
|
| Hepatocyte Nuclear Factor 3-beta | 1 | 2017 | 12 | 0.130 |
Why?
|
| Algorithms | 3 | 2025 | 1845 | 0.130 |
Why?
|
| Radiography | 6 | 2005 | 852 | 0.130 |
Why?
|
| Drug Administration Schedule | 1 | 2019 | 781 | 0.130 |
Why?
|
| Minor Histocompatibility Antigens | 1 | 2017 | 47 | 0.130 |
Why?
|
| Dinucleoside Phosphates | 1 | 1997 | 31 | 0.130 |
Why?
|
| Pentoxifylline | 1 | 1997 | 23 | 0.130 |
Why?
|
| Salivary Glands | 1 | 2017 | 36 | 0.130 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2009 | 288 | 0.130 |
Why?
|
| Nicotine | 1 | 2020 | 330 | 0.130 |
Why?
|
| Flow Cytometry | 3 | 2013 | 1159 | 0.130 |
Why?
|
| RNA, Small Interfering | 2 | 2017 | 634 | 0.130 |
Why?
|
| Sensitivity and Specificity | 7 | 2021 | 1995 | 0.130 |
Why?
|
| Antimicrobial Stewardship | 1 | 2019 | 130 | 0.130 |
Why?
|
| Antibodies, Phospho-Specific | 1 | 2017 | 2 | 0.130 |
Why?
|
| Sex Factors | 7 | 2018 | 2099 | 0.130 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2017 | 139 | 0.130 |
Why?
|
| Salivary Gland Neoplasms | 1 | 2017 | 39 | 0.130 |
Why?
|
| Pilot Projects | 3 | 2021 | 1889 | 0.130 |
Why?
|
| Middle East | 3 | 2002 | 18 | 0.130 |
Why?
|
| Temporomandibular Joint Disorders | 1 | 2016 | 7 | 0.130 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 1997 | 73 | 0.130 |
Why?
|
| Arrestins | 2 | 2009 | 14 | 0.130 |
Why?
|
| Bronchoconstrictor Agents | 4 | 2011 | 14 | 0.130 |
Why?
|
| Protein Binding | 2 | 2017 | 2235 | 0.120 |
Why?
|
| A Kinase Anchor Proteins | 1 | 2017 | 70 | 0.120 |
Why?
|
| Administration, Intranasal | 1 | 2017 | 94 | 0.120 |
Why?
|
| Blood | 3 | 2008 | 107 | 0.120 |
Why?
|
| Down-Regulation | 1 | 2019 | 618 | 0.120 |
Why?
|
| Gastroesophageal Reflux | 1 | 2019 | 236 | 0.120 |
Why?
|
| Joint Prosthesis | 1 | 2016 | 22 | 0.120 |
Why?
|
| Myocardial Contraction | 2 | 2015 | 291 | 0.120 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2020 | 268 | 0.120 |
Why?
|
| Fear | 1 | 2020 | 367 | 0.120 |
Why?
|
| NIH 3T3 Cells | 1 | 2017 | 146 | 0.120 |
Why?
|
| RNA, Viral | 1 | 2020 | 690 | 0.120 |
Why?
|
| Environmental Pollutants | 2 | 2011 | 138 | 0.120 |
Why?
|
| Immunity, Cellular | 2 | 2017 | 273 | 0.120 |
Why?
|
| Cell Adhesion | 3 | 2014 | 451 | 0.120 |
Why?
|
| Glioblastoma | 1 | 2020 | 352 | 0.120 |
Why?
|
| Cell Division | 5 | 2004 | 753 | 0.120 |
Why?
|
| Patient Care | 1 | 2017 | 119 | 0.120 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2012 | 977 | 0.120 |
Why?
|
| Mass Screening | 2 | 2018 | 1354 | 0.120 |
Why?
|
| Interferon-alpha | 1 | 1997 | 193 | 0.120 |
Why?
|
| Immunity, Humoral | 1 | 2017 | 118 | 0.120 |
Why?
|
| Antibodies | 2 | 2017 | 397 | 0.120 |
Why?
|
| Gene Knockdown Techniques | 1 | 2017 | 333 | 0.120 |
Why?
|
| Databases, Factual | 2 | 2019 | 1488 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2016 | 46 | 0.120 |
Why?
|
| Gram-Positive Bacteria | 1 | 2016 | 48 | 0.120 |
Why?
|
| Arthroplasty, Replacement | 1 | 2016 | 47 | 0.120 |
Why?
|
| Pulmonary Diffusing Capacity | 7 | 2005 | 78 | 0.120 |
Why?
|
| Trypanosoma cruzi | 2 | 2015 | 39 | 0.120 |
Why?
|
| Endosonography | 1 | 2017 | 160 | 0.120 |
Why?
|
| Plasma | 1 | 2017 | 223 | 0.120 |
Why?
|
| Microscopy, Confocal | 1 | 2017 | 318 | 0.120 |
Why?
|
| Colonoscopy | 3 | 2026 | 262 | 0.120 |
Why?
|
| Risk | 3 | 2015 | 916 | 0.110 |
Why?
|
| Esophagectomy | 1 | 2017 | 135 | 0.110 |
Why?
|
| Hydrocortisone | 1 | 1998 | 298 | 0.110 |
Why?
|
| Sus scrofa | 2 | 2021 | 63 | 0.110 |
Why?
|
| Extracellular Matrix Proteins | 2 | 2007 | 156 | 0.110 |
Why?
|
| Carbon Monoxide | 2 | 2012 | 82 | 0.110 |
Why?
|
| Transplantation, Homologous | 3 | 2007 | 417 | 0.110 |
Why?
|
| Alcohol Drinking | 1 | 2022 | 836 | 0.110 |
Why?
|
| Matrix Metalloproteinase 9 | 2 | 2008 | 130 | 0.110 |
Why?
|
| Peak Expiratory Flow Rate | 1 | 1995 | 25 | 0.110 |
Why?
|
| Core Binding Factor Alpha 3 Subunit | 1 | 2015 | 6 | 0.110 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2013 | 337 | 0.110 |
Why?
|
| Antigens, Dermatophagoides | 2 | 2014 | 10 | 0.110 |
Why?
|
| Self Efficacy | 1 | 2019 | 410 | 0.110 |
Why?
|
| Hospitals | 1 | 2020 | 732 | 0.110 |
Why?
|
| beta-Cyclodextrins | 1 | 2015 | 32 | 0.110 |
Why?
|
| Delivery of Health Care | 1 | 2022 | 946 | 0.110 |
Why?
|
| Immunoconjugates | 1 | 2017 | 138 | 0.110 |
Why?
|
| Central Nervous System Stimulants | 1 | 2017 | 185 | 0.110 |
Why?
|
| Trachea | 3 | 2009 | 258 | 0.110 |
Why?
|
| Interleukin-1 Receptor-Like 1 Protein | 1 | 2015 | 22 | 0.110 |
Why?
|
| Communicable Diseases | 1 | 2017 | 166 | 0.110 |
Why?
|
| Acetylcysteine | 1 | 2015 | 139 | 0.110 |
Why?
|
| Weight Gain | 1 | 2019 | 561 | 0.110 |
Why?
|
| Patient Participation | 1 | 2019 | 437 | 0.110 |
Why?
|
| Research | 4 | 2005 | 430 | 0.110 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2008 | 666 | 0.110 |
Why?
|
| Pseudomonas aeruginosa | 3 | 2009 | 395 | 0.110 |
Why?
|
| Remission Induction | 3 | 2025 | 306 | 0.110 |
Why?
|
| NF-kappa B | 3 | 2014 | 664 | 0.110 |
Why?
|
| Amino Acid Substitution | 3 | 2025 | 302 | 0.110 |
Why?
|
| Mice, 129 Strain | 2 | 2012 | 84 | 0.110 |
Why?
|
| Coronary Circulation | 1 | 2015 | 134 | 0.110 |
Why?
|
| Antibodies, Monoclonal | 2 | 2017 | 1505 | 0.110 |
Why?
|
| Repressor Proteins | 2 | 2020 | 429 | 0.110 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2024 | 1958 | 0.110 |
Why?
|
| Gene-Environment Interaction | 2 | 2014 | 178 | 0.100 |
Why?
|
| Isoleucine | 1 | 2014 | 15 | 0.100 |
Why?
|
| Interleukins | 1 | 1996 | 248 | 0.100 |
Why?
|
| Antigens, Protozoan | 2 | 2012 | 32 | 0.100 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2019 | 640 | 0.100 |
Why?
|
| Nerve Net | 1 | 2017 | 284 | 0.100 |
Why?
|
| Threonine | 1 | 2014 | 44 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2015 | 440 | 0.100 |
Why?
|
| Computational Biology | 3 | 2009 | 669 | 0.100 |
Why?
|
| Proto-Oncogenes | 1 | 1994 | 28 | 0.100 |
Why?
|
| Ribonucleoprotein, U5 Small Nuclear | 1 | 2013 | 11 | 0.100 |
Why?
|
| Cluster Analysis | 4 | 2022 | 500 | 0.100 |
Why?
|
| Peptide Elongation Factors | 1 | 2013 | 15 | 0.100 |
Why?
|
| Societies, Medical | 3 | 2025 | 898 | 0.100 |
Why?
|
| Macrophage Migration-Inhibitory Factors | 1 | 2013 | 12 | 0.100 |
Why?
|
| Martial Arts | 1 | 2013 | 3 | 0.100 |
Why?
|
| Genes, ras | 1 | 1994 | 96 | 0.100 |
Why?
|
| Students | 1 | 2019 | 650 | 0.100 |
Why?
|
| Orthodontic Appliances, Removable | 1 | 2013 | 2 | 0.100 |
Why?
|
| Evidence-Based Medicine | 1 | 2017 | 739 | 0.100 |
Why?
|
| Postoperative Complications | 4 | 2023 | 2961 | 0.100 |
Why?
|
| Dentistry | 1 | 2013 | 9 | 0.100 |
Why?
|
| Sleep Medicine Specialty | 1 | 2013 | 10 | 0.100 |
Why?
|
| Air Pollution | 1 | 2017 | 312 | 0.100 |
Why?
|
| Prolactinoma | 1 | 2013 | 13 | 0.100 |
Why?
|
| Intramolecular Oxidoreductases | 1 | 2013 | 65 | 0.100 |
Why?
|
| Homeostasis | 3 | 2009 | 639 | 0.100 |
Why?
|
| Swimming | 1 | 2013 | 54 | 0.100 |
Why?
|
| Glucocorticoids | 1 | 1998 | 531 | 0.100 |
Why?
|
| Vehicle Emissions | 1 | 2013 | 57 | 0.100 |
Why?
|
| Membrane Proteins | 3 | 2016 | 1163 | 0.100 |
Why?
|
| HLA-A Antigens | 1 | 1993 | 52 | 0.100 |
Why?
|
| Sensation | 1 | 2013 | 55 | 0.100 |
Why?
|
| Saskatchewan | 3 | 2021 | 8 | 0.100 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2014 | 203 | 0.100 |
Why?
|
| Neoplasms | 2 | 2021 | 2900 | 0.100 |
Why?
|
| Nitric Oxide Synthase Type II | 4 | 2024 | 162 | 0.100 |
Why?
|
| Genetic Diseases, X-Linked | 1 | 2013 | 26 | 0.100 |
Why?
|
| Critical Care | 1 | 2019 | 702 | 0.100 |
Why?
|
| Agammaglobulinemia | 1 | 2013 | 36 | 0.100 |
Why?
|
| HLA-B Antigens | 1 | 1993 | 58 | 0.100 |
Why?
|
| Chromosomes, Human | 1 | 2013 | 42 | 0.100 |
Why?
|
| Evolution, Molecular | 2 | 2025 | 490 | 0.100 |
Why?
|
| Myofibroblasts | 2 | 2026 | 144 | 0.100 |
Why?
|
| Cocaine | 1 | 2015 | 161 | 0.100 |
Why?
|
| Intensive Care Units, Neonatal | 3 | 2022 | 291 | 0.100 |
Why?
|
| Medication Adherence | 1 | 2017 | 540 | 0.100 |
Why?
|
| Physical Exertion | 1 | 1994 | 205 | 0.100 |
Why?
|
| Coal Ash | 2 | 2004 | 8 | 0.090 |
Why?
|
| Pulmonary Surfactants | 3 | 2016 | 104 | 0.090 |
Why?
|
| Brain | 3 | 2021 | 2934 | 0.090 |
Why?
|
| Biology | 2 | 2023 | 88 | 0.090 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2019 | 1415 | 0.090 |
Why?
|
| Wounds and Injuries | 2 | 2002 | 960 | 0.090 |
Why?
|
| HLA-DQ Antigens | 1 | 1993 | 174 | 0.090 |
Why?
|
| Sarcoidosis, Pulmonary | 1 | 1994 | 98 | 0.090 |
Why?
|
| Protein Interaction Maps | 1 | 2012 | 51 | 0.090 |
Why?
|
| Esophageal Neoplasms | 1 | 2017 | 345 | 0.090 |
Why?
|
| Bone Marrow | 3 | 2010 | 306 | 0.090 |
Why?
|
| Solubility | 2 | 2017 | 240 | 0.090 |
Why?
|
| HLA-DR Antigens | 1 | 1993 | 220 | 0.090 |
Why?
|
| H-2 Antigens | 1 | 2012 | 111 | 0.090 |
Why?
|
| Methotrexate | 3 | 2021 | 233 | 0.090 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2015 | 355 | 0.090 |
Why?
|
| Demography | 2 | 2024 | 282 | 0.090 |
Why?
|
| Cell Separation | 1 | 2013 | 304 | 0.090 |
Why?
|
| Physical Fitness | 1 | 2013 | 207 | 0.090 |
Why?
|
| Skin Neoplasms | 1 | 2019 | 848 | 0.090 |
Why?
|
| Decision Making | 1 | 2019 | 974 | 0.090 |
Why?
|
| Histamine | 1 | 1992 | 52 | 0.090 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2012 | 50 | 0.090 |
Why?
|
| Hirschsprung Disease | 1 | 2013 | 92 | 0.090 |
Why?
|
| Models, Genetic | 2 | 2021 | 523 | 0.090 |
Why?
|
| Bone Marrow Cells | 1 | 2013 | 320 | 0.090 |
Why?
|
| Colorectal Neoplasms | 1 | 2020 | 864 | 0.090 |
Why?
|
| Bronchitis | 2 | 2002 | 29 | 0.090 |
Why?
|
| Observer Variation | 1 | 2012 | 356 | 0.090 |
Why?
|
| Aluminum Silicates | 1 | 1991 | 17 | 0.090 |
Why?
|
| Caspases, Initiator | 1 | 2011 | 16 | 0.090 |
Why?
|
| Amino Acid Sequence | 4 | 2011 | 2127 | 0.090 |
Why?
|
| Sample Size | 2 | 2022 | 121 | 0.090 |
Why?
|
| Learning | 2 | 2021 | 443 | 0.090 |
Why?
|
| Carbon | 2 | 2004 | 176 | 0.090 |
Why?
|
| Pulmonary Ventilation | 3 | 1997 | 82 | 0.090 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2014 | 483 | 0.090 |
Why?
|
| Europe | 3 | 2022 | 416 | 0.080 |
Why?
|
| beta-Lactam Resistance | 1 | 2011 | 10 | 0.080 |
Why?
|
| Pituitary Neoplasms | 1 | 2013 | 190 | 0.080 |
Why?
|
| Actins | 2 | 2026 | 424 | 0.080 |
Why?
|
| Myocarditis | 1 | 2012 | 102 | 0.080 |
Why?
|
| Collagen | 2 | 2006 | 455 | 0.080 |
Why?
|
| Nitric Oxide | 3 | 2014 | 892 | 0.080 |
Why?
|
| Finland | 2 | 2019 | 78 | 0.080 |
Why?
|
| Alzheimer Disease | 1 | 2017 | 629 | 0.080 |
Why?
|
| Immunocompromised Host | 1 | 2012 | 202 | 0.080 |
Why?
|
| Brain Neoplasms | 1 | 2020 | 1328 | 0.080 |
Why?
|
| Cross-Over Studies | 3 | 1998 | 608 | 0.080 |
Why?
|
| Kinetics | 3 | 2025 | 1567 | 0.080 |
Why?
|
| Postural Balance | 1 | 2013 | 244 | 0.080 |
Why?
|
| Caspases | 1 | 2011 | 233 | 0.080 |
Why?
|
| Killer Cells, Natural | 1 | 2013 | 478 | 0.080 |
Why?
|
| Phosphorylation | 2 | 2017 | 1706 | 0.080 |
Why?
|
| Accidents, Occupational | 1 | 1990 | 18 | 0.080 |
Why?
|
| Maintenance Chemotherapy | 2 | 2021 | 42 | 0.080 |
Why?
|
| Melanoma | 1 | 2017 | 759 | 0.080 |
Why?
|
| Haplotypes | 3 | 2021 | 498 | 0.080 |
Why?
|
| Gases | 1 | 1990 | 46 | 0.080 |
Why?
|
| Paternal Age | 1 | 1989 | 3 | 0.080 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2013 | 299 | 0.080 |
Why?
|
| Chlorine | 1 | 1990 | 59 | 0.080 |
Why?
|
| Latin America | 2 | 2025 | 96 | 0.080 |
Why?
|
| Serratia marcescens | 1 | 2009 | 17 | 0.080 |
Why?
|
| Surveys and Questionnaires | 6 | 2020 | 6055 | 0.080 |
Why?
|
| Pulmonary Surfactant-Associated Protein D | 2 | 2025 | 31 | 0.080 |
Why?
|
| Tumor Microenvironment | 2 | 2025 | 733 | 0.080 |
Why?
|
| Pneumonia, Ventilator-Associated | 1 | 2010 | 58 | 0.080 |
Why?
|
| Chemokine CXCL1 | 1 | 2009 | 76 | 0.080 |
Why?
|
| Acute Lung Injury | 1 | 2013 | 305 | 0.080 |
Why?
|
| Plethysmography | 2 | 2004 | 104 | 0.070 |
Why?
|
| Electronic Health Records | 1 | 2017 | 1188 | 0.070 |
Why?
|
| Growth Substances | 1 | 1989 | 138 | 0.070 |
Why?
|
| Metallothionein | 1 | 2009 | 25 | 0.070 |
Why?
|
| Chemotaxis, Leukocyte | 2 | 2012 | 113 | 0.070 |
Why?
|
| Telephone | 2 | 2021 | 177 | 0.070 |
Why?
|
| Family | 2 | 2025 | 682 | 0.070 |
Why?
|
| Pyroglyphidae | 2 | 2023 | 18 | 0.070 |
Why?
|
| Endothelial Cells | 2 | 2023 | 873 | 0.070 |
Why?
|
| Iceland | 2 | 2019 | 11 | 0.070 |
Why?
|
| Bacteria | 1 | 2014 | 765 | 0.070 |
Why?
|
| Cell Proliferation | 2 | 2025 | 2504 | 0.070 |
Why?
|
| Motor Activity | 1 | 2013 | 718 | 0.070 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2009 | 264 | 0.070 |
Why?
|
| Mice, Inbred AKR | 1 | 2008 | 35 | 0.070 |
Why?
|
| Mice, Inbred NZB | 1 | 2008 | 16 | 0.070 |
Why?
|
| Nitric Oxide Synthase | 2 | 2006 | 234 | 0.070 |
Why?
|
| Genome | 1 | 2011 | 304 | 0.070 |
Why?
|
| Mice, Inbred A | 1 | 2008 | 48 | 0.070 |
Why?
|
| Forkhead Transcription Factors | 1 | 2009 | 207 | 0.070 |
Why?
|
| Magnetoencephalography | 2 | 2021 | 161 | 0.070 |
Why?
|
| Mice, Inbred MRL lpr | 1 | 2008 | 36 | 0.070 |
Why?
|
| Mycology | 1 | 2008 | 5 | 0.070 |
Why?
|
| Gene Library | 1 | 2008 | 122 | 0.070 |
Why?
|
| Procollagen | 1 | 2008 | 24 | 0.070 |
Why?
|
| Fungemia | 1 | 2008 | 10 | 0.070 |
Why?
|
| Aspergillus fumigatus | 1 | 2008 | 26 | 0.070 |
Why?
|
| Glucagon-Like Peptide 1 | 1 | 2009 | 148 | 0.070 |
Why?
|
| Up-Regulation | 3 | 2013 | 846 | 0.070 |
Why?
|
| Bronchoscopy | 3 | 2014 | 227 | 0.070 |
Why?
|
| Guidelines as Topic | 2 | 2021 | 266 | 0.070 |
Why?
|
| Single-Blind Method | 3 | 1998 | 316 | 0.070 |
Why?
|
| Rhinitis, Allergic, Seasonal | 1 | 2008 | 25 | 0.070 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 2008 | 156 | 0.070 |
Why?
|
| Paint | 1 | 1988 | 8 | 0.070 |
Why?
|
| Candida | 1 | 2008 | 45 | 0.070 |
Why?
|
| Adenoviridae | 2 | 2006 | 199 | 0.070 |
Why?
|
| Candidiasis | 1 | 2008 | 64 | 0.070 |
Why?
|
| Germ-Line Mutation | 2 | 2020 | 176 | 0.070 |
Why?
|
| Immunoglobulin G | 4 | 2023 | 887 | 0.070 |
Why?
|
| Brachiocephalic Veins | 1 | 2007 | 4 | 0.070 |
Why?
|
| Predictive Value of Tests | 5 | 2015 | 2115 | 0.070 |
Why?
|
| Immune Complex Diseases | 1 | 2007 | 5 | 0.070 |
Why?
|
| Chemotactic Factors | 2 | 1998 | 43 | 0.070 |
Why?
|
| Chemokine CCL5 | 1 | 2007 | 40 | 0.070 |
Why?
|
| Feces | 1 | 2011 | 494 | 0.070 |
Why?
|
| Protein Interaction Mapping | 1 | 2008 | 105 | 0.070 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2019 | 221 | 0.070 |
Why?
|
| Catheters, Indwelling | 1 | 2008 | 96 | 0.070 |
Why?
|
| Arteriovenous Shunt, Surgical | 1 | 2007 | 20 | 0.070 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2008 | 139 | 0.060 |
Why?
|
| Recombination, Genetic | 2 | 2005 | 203 | 0.060 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2007 | 40 | 0.060 |
Why?
|
| Dinoprostone | 2 | 2001 | 180 | 0.060 |
Why?
|
| Azacitidine | 1 | 2008 | 157 | 0.060 |
Why?
|
| Liver | 3 | 2012 | 1893 | 0.060 |
Why?
|
| Heart Rate | 2 | 2015 | 855 | 0.060 |
Why?
|
| Placebos | 2 | 1998 | 193 | 0.060 |
Why?
|
| Lung Compliance | 1 | 2007 | 42 | 0.060 |
Why?
|
| Recombinant Proteins | 3 | 2005 | 1368 | 0.060 |
Why?
|
| Cytokinesis | 1 | 2007 | 50 | 0.060 |
Why?
|
| Cystic Fibrosis | 1 | 1997 | 1160 | 0.060 |
Why?
|
| Tumor Cells, Cultured | 2 | 2001 | 886 | 0.060 |
Why?
|
| Software | 1 | 2012 | 678 | 0.060 |
Why?
|
| Human Experimentation | 1 | 2006 | 12 | 0.060 |
Why?
|
| Aerosols | 2 | 2001 | 145 | 0.060 |
Why?
|
| Arm | 1 | 2007 | 110 | 0.060 |
Why?
|
| Neutrophil Activation | 1 | 2007 | 84 | 0.060 |
Why?
|
| Gene Deletion | 2 | 2012 | 391 | 0.060 |
Why?
|
| Crosses, Genetic | 2 | 2011 | 123 | 0.060 |
Why?
|
| Chemokine CCL2 | 1 | 2007 | 112 | 0.060 |
Why?
|
| Ethics, Research | 1 | 2006 | 31 | 0.060 |
Why?
|
| Antimicrobial Cationic Peptides | 1 | 2007 | 81 | 0.060 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2004 | 698 | 0.060 |
Why?
|
| Disease-Free Survival | 2 | 2020 | 766 | 0.060 |
Why?
|
| Protein Subunits | 1 | 2007 | 229 | 0.060 |
Why?
|
| Adenocarcinoma | 1 | 1994 | 920 | 0.060 |
Why?
|
| Chemokines, CXC | 1 | 2006 | 68 | 0.060 |
Why?
|
| Organ Specificity | 1 | 2007 | 308 | 0.060 |
Why?
|
| Monocytes | 1 | 1989 | 537 | 0.060 |
Why?
|
| Chimera | 1 | 2006 | 60 | 0.060 |
Why?
|
| Lymphokines | 1 | 2006 | 128 | 0.060 |
Why?
|
| X-Box Binding Protein 1 | 1 | 2026 | 16 | 0.060 |
Why?
|
| Cell Count | 2 | 1998 | 319 | 0.060 |
Why?
|
| Uteroglobin | 1 | 2026 | 30 | 0.060 |
Why?
|
| Thrombosis | 2 | 2025 | 401 | 0.060 |
Why?
|
| Chemokine CXCL12 | 1 | 2006 | 86 | 0.060 |
Why?
|
| Nitrites | 1 | 2006 | 87 | 0.060 |
Why?
|
| Receptors, CXCR4 | 1 | 2006 | 91 | 0.060 |
Why?
|
| Brachial Artery | 1 | 2007 | 208 | 0.060 |
Why?
|
| Ear, Middle | 2 | 2018 | 84 | 0.060 |
Why?
|
| Response Elements | 1 | 2006 | 86 | 0.060 |
Why?
|
| beta-Lactamase Inhibitors | 1 | 2025 | 9 | 0.060 |
Why?
|
| Enzyme Activation | 1 | 2007 | 762 | 0.060 |
Why?
|
| Postal Service | 2 | 1996 | 27 | 0.060 |
Why?
|
| Organizational Policy | 1 | 2006 | 78 | 0.060 |
Why?
|
| Acinetobacter Infections | 1 | 2025 | 15 | 0.060 |
Why?
|
| Cell Culture Techniques | 1 | 2008 | 372 | 0.060 |
Why?
|
| Bias | 1 | 2006 | 197 | 0.060 |
Why?
|
| Genes, Recessive | 1 | 2005 | 78 | 0.060 |
Why?
|
| Agar | 2 | 2018 | 11 | 0.060 |
Why?
|
| Wnt Proteins | 1 | 2006 | 133 | 0.060 |
Why?
|
| Models, Biological | 3 | 2013 | 1763 | 0.060 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2026 | 53 | 0.060 |
Why?
|
| S-Nitrosothiols | 1 | 2005 | 5 | 0.060 |
Why?
|
| S-Nitrosoglutathione | 1 | 2005 | 8 | 0.060 |
Why?
|
| Glutathione Reductase | 1 | 2005 | 24 | 0.060 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 2005 | 117 | 0.060 |
Why?
|
| Body Mass Index | 2 | 2015 | 2437 | 0.060 |
Why?
|
| Military Personnel | 3 | 2004 | 736 | 0.060 |
Why?
|
| Antibody Formation | 2 | 2024 | 287 | 0.060 |
Why?
|
| Transplantation, Heterotopic | 1 | 2005 | 16 | 0.060 |
Why?
|
| Patient Compliance | 2 | 2020 | 587 | 0.050 |
Why?
|
| Cloning, Molecular | 2 | 2023 | 537 | 0.050 |
Why?
|
| Enzyme Inhibitors | 1 | 2008 | 820 | 0.050 |
Why?
|
| Acute Kidney Injury | 1 | 2013 | 872 | 0.050 |
Why?
|
| Interferons | 1 | 2006 | 186 | 0.050 |
Why?
|
| Research Support as Topic | 1 | 2005 | 80 | 0.050 |
Why?
|
| Chimerism | 1 | 2004 | 35 | 0.050 |
Why?
|
| Substrate Specificity | 1 | 2025 | 383 | 0.050 |
Why?
|
| Genetic Vectors | 1 | 2006 | 335 | 0.050 |
Why?
|
| Receptor, trkC | 1 | 2024 | 10 | 0.050 |
Why?
|
| Stress Disorders, Post-Traumatic | 2 | 2004 | 890 | 0.050 |
Why?
|
| Mice, Mutant Strains | 2 | 2003 | 302 | 0.050 |
Why?
|
| T-Lymphocytes | 3 | 2009 | 1993 | 0.050 |
Why?
|
| Body Temperature | 1 | 2006 | 227 | 0.050 |
Why?
|
| DNA Primers | 2 | 1997 | 505 | 0.050 |
Why?
|
| Tryptophan Hydroxylase | 1 | 2005 | 54 | 0.050 |
Why?
|
| Lymphocyte Count | 1 | 2004 | 163 | 0.050 |
Why?
|
| Oxidative Stress | 2 | 2009 | 1351 | 0.050 |
Why?
|
| Th17 Cells | 1 | 2025 | 100 | 0.050 |
Why?
|
| I-kappa B Kinase | 1 | 2004 | 51 | 0.050 |
Why?
|
| Superoxide Dismutase | 1 | 2006 | 307 | 0.050 |
Why?
|
| Sputum | 2 | 1997 | 302 | 0.050 |
Why?
|
| Virulence | 1 | 2025 | 278 | 0.050 |
Why?
|
| Peroxidase | 1 | 2004 | 168 | 0.050 |
Why?
|
| Reference Values | 2 | 2000 | 798 | 0.050 |
Why?
|
| Molecular Biology | 1 | 2004 | 57 | 0.050 |
Why?
|
| Pulmonary Edema | 1 | 2004 | 105 | 0.050 |
Why?
|
| K562 Cells | 1 | 2024 | 92 | 0.050 |
Why?
|
| Meta-Analysis as Topic | 1 | 2025 | 169 | 0.050 |
Why?
|
| Fever | 1 | 2006 | 318 | 0.050 |
Why?
|
| Lakes | 1 | 2024 | 23 | 0.050 |
Why?
|
| beta-Galactosidase | 2 | 2002 | 76 | 0.050 |
Why?
|
| Tertiary Care Centers | 1 | 2025 | 195 | 0.050 |
Why?
|
| Respiratory Physiological Phenomena | 1 | 2004 | 35 | 0.050 |
Why?
|
| Propensity Score | 1 | 2026 | 374 | 0.050 |
Why?
|
| Probability | 1 | 2005 | 307 | 0.050 |
Why?
|
| Microsatellite Repeats | 1 | 2005 | 156 | 0.050 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 2 | 2016 | 296 | 0.050 |
Why?
|
| Health Services Accessibility | 2 | 2025 | 1099 | 0.050 |
Why?
|
| DNA, Mitochondrial | 1 | 2005 | 211 | 0.050 |
Why?
|
| Food Hypersensitivity | 1 | 2026 | 164 | 0.050 |
Why?
|
| Rural Population | 1 | 2009 | 657 | 0.050 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2024 | 76 | 0.050 |
Why?
|
| Trypanosoma brucei brucei | 1 | 2003 | 7 | 0.050 |
Why?
|
| DNA, Protozoan | 1 | 2003 | 32 | 0.050 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2008 | 909 | 0.050 |
Why?
|
| Lymphocyte Activation | 1 | 2007 | 1131 | 0.050 |
Why?
|
| Linear Models | 3 | 2015 | 844 | 0.050 |
Why?
|
| Biological Therapy | 1 | 2023 | 28 | 0.050 |
Why?
|
| Democratic Republic of the Congo | 1 | 2023 | 33 | 0.050 |
Why?
|
| Drug Resistance | 1 | 2004 | 145 | 0.050 |
Why?
|
| Renal Dialysis | 1 | 2007 | 466 | 0.050 |
Why?
|
| Respiration, Artificial | 2 | 2004 | 713 | 0.050 |
Why?
|
| Bronchitis, Chronic | 1 | 2003 | 16 | 0.050 |
Why?
|
| Therapeutic Irrigation | 1 | 2003 | 68 | 0.050 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2003 | 85 | 0.050 |
Why?
|
| Receptors, Lysophosphatidic Acid | 1 | 2023 | 40 | 0.050 |
Why?
|
| Interleukin-5 | 1 | 2003 | 39 | 0.050 |
Why?
|
| Petroleum | 1 | 2002 | 10 | 0.050 |
Why?
|
| CD18 Antigens | 1 | 2002 | 21 | 0.050 |
Why?
|
| DNA-Binding Proteins | 2 | 2020 | 1479 | 0.050 |
Why?
|
| Protein Structure, Tertiary | 2 | 2003 | 855 | 0.050 |
Why?
|
| Academic Medical Centers | 2 | 2021 | 552 | 0.050 |
Why?
|
| Carcinoma | 1 | 2024 | 224 | 0.050 |
Why?
|
| Tissue Inhibitor of Metalloproteinases | 1 | 2002 | 16 | 0.050 |
Why?
|
| Teichoic Acids | 1 | 2002 | 18 | 0.050 |
Why?
|
| CRISPR-Cas Systems | 1 | 2024 | 166 | 0.050 |
Why?
|
| HEK293 Cells | 2 | 2018 | 740 | 0.050 |
Why?
|
| Animals, Wild | 1 | 2022 | 60 | 0.050 |
Why?
|
| Geographic Information Systems | 1 | 2002 | 45 | 0.050 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2024 | 212 | 0.050 |
Why?
|
| Serotonin | 1 | 2005 | 296 | 0.050 |
Why?
|
| Fetal Distress | 1 | 2022 | 14 | 0.050 |
Why?
|
| Proteolipids | 1 | 2002 | 28 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 2 | 2021 | 1579 | 0.050 |
Why?
|
| Pulmonary Medicine | 1 | 2003 | 78 | 0.050 |
Why?
|
| DNA Damage | 1 | 2005 | 435 | 0.050 |
Why?
|
| Genetic Testing | 3 | 2017 | 480 | 0.040 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2023 | 187 | 0.040 |
Why?
|
| Carcinogens | 1 | 2002 | 123 | 0.040 |
Why?
|
| Combat Disorders | 1 | 2002 | 42 | 0.040 |
Why?
|
| Aniline Compounds | 1 | 2023 | 120 | 0.040 |
Why?
|
| Carotid Artery Diseases | 1 | 2002 | 70 | 0.040 |
Why?
|
| Bloom Syndrome | 1 | 2001 | 3 | 0.040 |
Why?
|
| Plethysmography, Whole Body | 1 | 2001 | 3 | 0.040 |
Why?
|
| Protease Inhibitors | 1 | 2002 | 102 | 0.040 |
Why?
|
| Cutaneous Fistula | 1 | 2021 | 14 | 0.040 |
Why?
|
| Intestinal Polyps | 1 | 2021 | 14 | 0.040 |
Why?
|
| Leukotriene B4 | 1 | 2001 | 36 | 0.040 |
Why?
|
| Cyclooxygenase 1 | 1 | 2001 | 27 | 0.040 |
Why?
|
| Immunoglobulin M | 1 | 2023 | 265 | 0.040 |
Why?
|
| Causality | 1 | 2002 | 126 | 0.040 |
Why?
|
| NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2023 | 166 | 0.040 |
Why?
|
| Neoplasm Staging | 2 | 2017 | 1467 | 0.040 |
Why?
|
| Cross Reactions | 1 | 2021 | 130 | 0.040 |
Why?
|
| Phylogeny | 1 | 2025 | 917 | 0.040 |
Why?
|
| Anastomotic Leak | 1 | 2021 | 45 | 0.040 |
Why?
|
| Kidney Failure, Chronic | 1 | 2007 | 599 | 0.040 |
Why?
|
| Injections, Intravenous | 2 | 1999 | 197 | 0.040 |
Why?
|
| INDEL Mutation | 1 | 2021 | 20 | 0.040 |
Why?
|
| Neurodevelopmental Disorders | 1 | 2024 | 226 | 0.040 |
Why?
|
| Vancomycin | 1 | 2022 | 94 | 0.040 |
Why?
|
| Anatomic Landmarks | 1 | 2021 | 31 | 0.040 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2001 | 45 | 0.040 |
Why?
|
| Antigens, Surface | 1 | 2001 | 155 | 0.040 |
Why?
|
| Carotid Arteries | 1 | 2002 | 208 | 0.040 |
Why?
|
| Cytochrome P-450 CYP2D6 | 1 | 2021 | 32 | 0.040 |
Why?
|
| Lac Operon | 1 | 2001 | 44 | 0.040 |
Why?
|
| Loss of Function Mutation | 1 | 2021 | 45 | 0.040 |
Why?
|
| Cyclooxygenase 2 | 1 | 2001 | 166 | 0.040 |
Why?
|
| Salaries and Fringe Benefits | 1 | 2021 | 57 | 0.040 |
Why?
|
| alpha Karyopherins | 1 | 2020 | 11 | 0.040 |
Why?
|
| Electroencephalography | 2 | 2021 | 561 | 0.040 |
Why?
|
| Staphylococcus aureus | 2 | 2016 | 451 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-ets | 1 | 2021 | 56 | 0.040 |
Why?
|
| Patient Satisfaction | 1 | 2025 | 708 | 0.040 |
Why?
|
| Lumbar Vertebrae | 1 | 2023 | 252 | 0.040 |
Why?
|
| Epilepsies, Partial | 1 | 2001 | 63 | 0.040 |
Why?
|
| Population Density | 1 | 2021 | 89 | 0.040 |
Why?
|
| Tripartite Motif Proteins | 1 | 2020 | 39 | 0.040 |
Why?
|
| Quality Control | 1 | 2021 | 161 | 0.040 |
Why?
|
| Anxiety Disorders | 1 | 2004 | 368 | 0.040 |
Why?
|
| Dioxygenases | 1 | 2020 | 34 | 0.040 |
Why?
|
| Thionucleotides | 1 | 2000 | 35 | 0.040 |
Why?
|
| Wilms Tumor | 1 | 2001 | 88 | 0.040 |
Why?
|
| Cell Self Renewal | 1 | 2020 | 52 | 0.040 |
Why?
|
| Evoked Potentials, Auditory | 1 | 2001 | 181 | 0.040 |
Why?
|
| Anastomosis, Surgical | 1 | 2021 | 162 | 0.040 |
Why?
|
| Africa | 1 | 2020 | 118 | 0.040 |
Why?
|
| Papillomavirus E7 Proteins | 1 | 2020 | 11 | 0.040 |
Why?
|
| HIV Envelope Protein gp120 | 1 | 2000 | 55 | 0.040 |
Why?
|
| Autoimmune Diseases | 1 | 2004 | 468 | 0.040 |
Why?
|
| Oncogene Proteins, Viral | 1 | 2020 | 20 | 0.040 |
Why?
|
| Spectroscopy, Fourier Transform Infrared | 1 | 2020 | 85 | 0.040 |
Why?
|
| Proof of Concept Study | 1 | 2020 | 89 | 0.040 |
Why?
|
| Policy | 1 | 2021 | 148 | 0.040 |
Why?
|
| TATA Box Binding Protein-Like Proteins | 1 | 2019 | 1 | 0.040 |
Why?
|
| Secondary Prevention | 1 | 2021 | 251 | 0.040 |
Why?
|
| HIV Antibodies | 1 | 2000 | 61 | 0.040 |
Why?
|
| beta Karyopherins | 1 | 2019 | 9 | 0.040 |
Why?
|
| Cesarean Section | 1 | 2022 | 229 | 0.040 |
Why?
|
| Premature Birth | 1 | 2024 | 387 | 0.040 |
Why?
|
| Precancerous Conditions | 1 | 2001 | 166 | 0.040 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 2000 | 141 | 0.040 |
Why?
|
| Mutagenesis | 1 | 2021 | 194 | 0.040 |
Why?
|
| Varenicline | 1 | 2020 | 28 | 0.040 |
Why?
|
| Trichinellosis | 1 | 2019 | 2 | 0.040 |
Why?
|
| Trichinella spiralis | 1 | 2019 | 2 | 0.040 |
Why?
|
| Cross Protection | 1 | 2019 | 5 | 0.040 |
Why?
|
| Faculty | 1 | 2021 | 147 | 0.040 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2020 | 77 | 0.040 |
Why?
|
| Bupropion | 1 | 2020 | 48 | 0.040 |
Why?
|
| Goblet Cells | 1 | 2019 | 22 | 0.040 |
Why?
|
| Midwestern United States | 1 | 2019 | 44 | 0.040 |
Why?
|
| Child Development | 1 | 2024 | 483 | 0.040 |
Why?
|
| Antibodies, Viral | 1 | 2024 | 673 | 0.040 |
Why?
|
| Th1 Cells | 1 | 2000 | 139 | 0.040 |
Why?
|
| Self Concept | 1 | 2021 | 253 | 0.040 |
Why?
|
| Antibodies, Bacterial | 1 | 2000 | 147 | 0.040 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2000 | 177 | 0.040 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2021 | 191 | 0.040 |
Why?
|
| Artifacts | 1 | 2020 | 143 | 0.040 |
Why?
|
| Mohs Surgery | 1 | 2019 | 29 | 0.040 |
Why?
|
| Dermatologic Surgical Procedures | 1 | 2019 | 23 | 0.040 |
Why?
|
| Biopsy | 4 | 2012 | 1079 | 0.040 |
Why?
|
| Philippines | 1 | 2019 | 51 | 0.040 |
Why?
|
| Margins of Excision | 1 | 2019 | 50 | 0.040 |
Why?
|
| Factor Analysis, Statistical | 1 | 2000 | 290 | 0.040 |
Why?
|
| Spindle Apparatus | 1 | 2020 | 95 | 0.040 |
Why?
|
| Pakistan | 1 | 2019 | 79 | 0.040 |
Why?
|
| Myeloid Differentiation Factor 88 | 2 | 2013 | 118 | 0.040 |
Why?
|
| Transfection | 1 | 2001 | 926 | 0.040 |
Why?
|
| Interviews as Topic | 2 | 2019 | 907 | 0.040 |
Why?
|
| STAT3 Transcription Factor | 1 | 2021 | 206 | 0.040 |
Why?
|
| Hospitals, Teaching | 1 | 2019 | 120 | 0.040 |
Why?
|
| Hyperplasia | 1 | 2019 | 177 | 0.040 |
Why?
|
| Virus Physiological Phenomena | 1 | 2018 | 9 | 0.040 |
Why?
|
| Gastric Acidity Determination | 1 | 1998 | 6 | 0.040 |
Why?
|
| Rural Health | 1 | 1999 | 87 | 0.040 |
Why?
|
| Blood Pressure | 1 | 2006 | 1778 | 0.040 |
Why?
|
| Postpartum Period | 1 | 2022 | 372 | 0.040 |
Why?
|
| Minority Groups | 1 | 2021 | 284 | 0.040 |
Why?
|
| Gestational Age | 1 | 2002 | 987 | 0.040 |
Why?
|
| Infection Control | 1 | 2020 | 173 | 0.040 |
Why?
|
| Homozygote | 2 | 2009 | 199 | 0.030 |
Why?
|
| Stem Cells | 1 | 2023 | 624 | 0.030 |
Why?
|
| Esophageal Diseases | 1 | 1998 | 30 | 0.030 |
Why?
|
| COS Cells | 1 | 2018 | 177 | 0.030 |
Why?
|
| Bacterial Physiological Phenomena | 1 | 2018 | 47 | 0.030 |
Why?
|
| Amiodarone | 1 | 1998 | 31 | 0.030 |
Why?
|
| Mitochondria | 1 | 2005 | 992 | 0.030 |
Why?
|
| Stomach | 1 | 1998 | 110 | 0.030 |
Why?
|
| Lymphatic Metastasis | 1 | 2019 | 331 | 0.030 |
Why?
|
| Antifungal Agents | 1 | 2019 | 150 | 0.030 |
Why?
|
| Ultrasonography | 1 | 2002 | 784 | 0.030 |
Why?
|
| Intention to Treat Analysis | 1 | 2018 | 79 | 0.030 |
Why?
|
| Environmental Pollution | 1 | 2018 | 20 | 0.030 |
Why?
|
| Graft vs Host Disease | 1 | 2001 | 278 | 0.030 |
Why?
|
| Health Services | 1 | 2019 | 113 | 0.030 |
Why?
|
| Tertiary Lymphoid Structures | 1 | 2017 | 7 | 0.030 |
Why?
|
| Premedication | 1 | 1998 | 45 | 0.030 |
Why?
|
| Rats | 4 | 2015 | 5582 | 0.030 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 1 | 1997 | 26 | 0.030 |
Why?
|
| Schools | 1 | 2021 | 448 | 0.030 |
Why?
|
| Endothelium, Vascular | 1 | 2004 | 955 | 0.030 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2001 | 371 | 0.030 |
Why?
|
| Rho Guanine Nucleotide Exchange Factors | 1 | 2017 | 27 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2019 | 506 | 0.030 |
Why?
|
| Neuroimaging | 1 | 2020 | 292 | 0.030 |
Why?
|
| Faculty, Medical | 1 | 2021 | 301 | 0.030 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2024 | 979 | 0.030 |
Why?
|
| Maternal Health | 1 | 2018 | 50 | 0.030 |
Why?
|
| Anesthesia, General | 1 | 1998 | 120 | 0.030 |
Why?
|
| Pulmonary Gas Exchange | 2 | 1995 | 116 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2025 | 3539 | 0.030 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 1998 | 144 | 0.030 |
Why?
|
| rhoA GTP-Binding Protein | 1 | 2017 | 76 | 0.030 |
Why?
|
| Kidney Neoplasms | 1 | 2001 | 412 | 0.030 |
Why?
|
| beta-Arrestin 2 | 2 | 2009 | 8 | 0.030 |
Why?
|
| Arthritis | 1 | 2018 | 96 | 0.030 |
Why?
|
| beta-Arrestins | 2 | 2009 | 15 | 0.030 |
Why?
|
| Contrast Media | 1 | 2020 | 497 | 0.030 |
Why?
|
| Penicillamine | 1 | 1996 | 18 | 0.030 |
Why?
|
| Eye Diseases | 1 | 2018 | 97 | 0.030 |
Why?
|
| Fasting | 1 | 1998 | 276 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 1998 | 428 | 0.030 |
Why?
|
| Conserved Sequence | 1 | 1997 | 244 | 0.030 |
Why?
|
| Antibody Specificity | 1 | 2017 | 177 | 0.030 |
Why?
|
| Chromatin | 1 | 2021 | 553 | 0.030 |
Why?
|
| Leadership | 1 | 2021 | 400 | 0.030 |
Why?
|
| 24,25-Dihydroxyvitamin D 3 | 1 | 1996 | 2 | 0.030 |
Why?
|
| Hypophosphatemia, Familial | 1 | 1996 | 4 | 0.030 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2016 | 85 | 0.030 |
Why?
|
| Workflow | 1 | 2018 | 183 | 0.030 |
Why?
|
| Hyperparathyroidism | 1 | 1996 | 11 | 0.030 |
Why?
|
| Polymyxin B | 1 | 1996 | 21 | 0.030 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2020 | 454 | 0.030 |
Why?
|
| Chemical Fractionation | 1 | 1996 | 29 | 0.030 |
Why?
|
| I-kappa B Proteins | 1 | 2016 | 75 | 0.030 |
Why?
|
| Folic Acid | 1 | 2018 | 198 | 0.030 |
Why?
|
| X Chromosome | 1 | 1996 | 65 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2016 | 67 | 0.030 |
Why?
|
| Gastrointestinal Diseases | 1 | 1998 | 221 | 0.030 |
Why?
|
| Models, Animal | 1 | 2018 | 393 | 0.030 |
Why?
|
| Child Health | 1 | 2018 | 153 | 0.030 |
Why?
|
| ADAMTS9 Protein | 1 | 2015 | 5 | 0.030 |
Why?
|
| Serpin E2 | 1 | 2015 | 5 | 0.030 |
Why?
|
| Procollagen N-Endopeptidase | 1 | 2015 | 7 | 0.030 |
Why?
|
| Microspheres | 1 | 1996 | 141 | 0.030 |
Why?
|
| Medicare | 1 | 2022 | 902 | 0.030 |
Why?
|
| ADAMTS4 Protein | 1 | 2015 | 16 | 0.030 |
Why?
|
| Radiotherapy | 1 | 2017 | 204 | 0.030 |
Why?
|
| Cell Cycle Proteins | 1 | 2020 | 629 | 0.030 |
Why?
|
| Serpins | 1 | 2015 | 28 | 0.030 |
Why?
|
| Emphysema | 1 | 2016 | 100 | 0.030 |
Why?
|
| Gold | 1 | 1996 | 116 | 0.030 |
Why?
|
| E-Selectin | 1 | 2015 | 61 | 0.030 |
Why?
|
| Aorta, Abdominal | 1 | 1996 | 52 | 0.030 |
Why?
|
| ADAM Proteins | 1 | 2015 | 64 | 0.030 |
Why?
|
| Depression, Chemical | 1 | 2015 | 16 | 0.030 |
Why?
|
| Stents | 1 | 2020 | 561 | 0.030 |
Why?
|
| Aspergillus oryzae | 1 | 2015 | 4 | 0.030 |
Why?
|
| Inpatients | 1 | 2020 | 552 | 0.030 |
Why?
|
| Pseudomonas Infections | 1 | 1997 | 230 | 0.030 |
Why?
|
| Fat Emulsions, Intravenous | 1 | 2015 | 29 | 0.030 |
Why?
|
| Cardiotoxicity | 1 | 2015 | 35 | 0.030 |
Why?
|
| Republic of Korea | 1 | 2015 | 43 | 0.030 |
Why?
|
| Bupivacaine | 1 | 2015 | 40 | 0.030 |
Why?
|
| Catheterization | 1 | 1996 | 183 | 0.030 |
Why?
|
| Liver Neoplasms | 1 | 2001 | 775 | 0.030 |
Why?
|
| Respiratory Sounds | 1 | 1995 | 103 | 0.030 |
Why?
|
| Personal Satisfaction | 1 | 2017 | 218 | 0.030 |
Why?
|
| Dermatophagoides pteronyssinus | 1 | 2014 | 3 | 0.030 |
Why?
|
| Residual Volume | 2 | 1995 | 5 | 0.030 |
Why?
|
| Blood Cells | 1 | 2014 | 38 | 0.030 |
Why?
|
| Treatment Failure | 2 | 2007 | 360 | 0.030 |
Why?
|
| Agriculture | 1 | 1995 | 93 | 0.030 |
Why?
|
| Bacterial Load | 1 | 2014 | 67 | 0.030 |
Why?
|
| Respiratory Dead Space | 1 | 1994 | 2 | 0.030 |
Why?
|
| Genotyping Techniques | 1 | 2014 | 71 | 0.030 |
Why?
|
| Genetics | 1 | 2014 | 23 | 0.030 |
Why?
|
| Plant Extracts | 1 | 1996 | 188 | 0.030 |
Why?
|
| Nebulizers and Vaporizers | 1 | 1994 | 62 | 0.030 |
Why?
|
| Cough | 1 | 1995 | 123 | 0.030 |
Why?
|
| Intensive Care Units | 2 | 2010 | 924 | 0.030 |
Why?
|
| Mexico | 1 | 2015 | 232 | 0.030 |
Why?
|
| Actuarial Analysis | 1 | 1994 | 16 | 0.030 |
Why?
|
| Mass Chest X-Ray | 1 | 1994 | 4 | 0.030 |
Why?
|
| Pain Measurement | 1 | 2016 | 554 | 0.030 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2013 | 28 | 0.030 |
Why?
|
| Hong Kong | 1 | 2013 | 7 | 0.030 |
Why?
|
| Random Allocation | 1 | 1995 | 365 | 0.030 |
Why?
|
| HLA-B44 Antigen | 1 | 1993 | 1 | 0.020 |
Why?
|
| Galactorrhea | 1 | 2013 | 1 | 0.020 |
Why?
|
| Gynecomastia | 1 | 2013 | 6 | 0.020 |
Why?
|
| HLA-DRB4 Chains | 1 | 1993 | 6 | 0.020 |
Why?
|
| Isotonic Solutions | 1 | 1993 | 42 | 0.020 |
Why?
|
| Models, Theoretical | 1 | 2017 | 556 | 0.020 |
Why?
|
| DNA, Neoplasm | 1 | 1994 | 158 | 0.020 |
Why?
|
| Bone and Bones | 1 | 1996 | 317 | 0.020 |
Why?
|
| Receptors, Aryl Hydrocarbon | 1 | 2013 | 60 | 0.020 |
Why?
|
| Equipment Design | 1 | 1995 | 525 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 1994 | 283 | 0.020 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 1996 | 445 | 0.020 |
Why?
|
| Interleukin-17 | 1 | 2013 | 120 | 0.020 |
Why?
|
| APACHE | 1 | 2013 | 68 | 0.020 |
Why?
|
| Toll-Like Receptor 1 | 1 | 2012 | 13 | 0.020 |
Why?
|
| Transendothelial and Transepithelial Migration | 1 | 2012 | 30 | 0.020 |
Why?
|
| Nerve Tissue Proteins | 1 | 2016 | 589 | 0.020 |
Why?
|
| DNA Probes | 1 | 2012 | 58 | 0.020 |
Why?
|
| Fibronectins | 1 | 1993 | 136 | 0.020 |
Why?
|
| Mitochondrial Proteins | 1 | 2015 | 263 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2019 | 1146 | 0.020 |
Why?
|
| Urine | 1 | 1993 | 64 | 0.020 |
Why?
|
| Programming Languages | 1 | 2012 | 24 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2017 | 1058 | 0.020 |
Why?
|
| Multigene Family | 1 | 2013 | 209 | 0.020 |
Why?
|
| Clinical Protocols | 1 | 1994 | 280 | 0.020 |
Why?
|
| Diarrhea | 1 | 2013 | 193 | 0.020 |
Why?
|
| Stem Cell Transplantation | 1 | 2013 | 189 | 0.020 |
Why?
|
| Abdominal Pain | 1 | 2013 | 149 | 0.020 |
Why?
|
| Social Environment | 1 | 2013 | 252 | 0.020 |
Why?
|
| Functional Residual Capacity | 1 | 1991 | 7 | 0.020 |
Why?
|
| Education | 1 | 2012 | 104 | 0.020 |
Why?
|
| Qualitative Research | 1 | 2019 | 1671 | 0.020 |
Why?
|
| Blood Coagulation Factors | 1 | 2012 | 71 | 0.020 |
Why?
|
| Alternative Splicing | 1 | 2013 | 247 | 0.020 |
Why?
|
| Lipoproteins | 1 | 2012 | 166 | 0.020 |
Why?
|
| Poly I-C | 1 | 2011 | 58 | 0.020 |
Why?
|
| Arthropod Proteins | 1 | 2011 | 6 | 0.020 |
Why?
|
| Antigens | 1 | 2013 | 348 | 0.020 |
Why?
|
| Heart | 1 | 2015 | 626 | 0.020 |
Why?
|
| Attitude of Health Personnel | 1 | 2019 | 1186 | 0.020 |
Why?
|
| Mast Cells | 1 | 1992 | 147 | 0.020 |
Why?
|
| Aza Compounds | 1 | 1990 | 12 | 0.020 |
Why?
|
| Cysteine Endopeptidases | 1 | 2011 | 74 | 0.020 |
Why?
|
| Spiro Compounds | 1 | 1990 | 17 | 0.020 |
Why?
|
| CHO Cells | 2 | 2001 | 169 | 0.020 |
Why?
|
| Greece | 1 | 2010 | 9 | 0.020 |
Why?
|
| Stress, Mechanical | 1 | 2012 | 494 | 0.020 |
Why?
|
| Cricetinae | 2 | 2001 | 302 | 0.020 |
Why?
|
| Metallurgy | 1 | 1990 | 9 | 0.020 |
Why?
|
| Listeriosis | 1 | 2011 | 63 | 0.020 |
Why?
|
| Urinary Tract Infections | 1 | 1993 | 210 | 0.020 |
Why?
|
| Sequence Alignment | 1 | 2011 | 362 | 0.020 |
Why?
|
| Germany | 1 | 2010 | 137 | 0.020 |
Why?
|
| Forced Expiratory Flow Rates | 1 | 2009 | 10 | 0.020 |
Why?
|
| Listeria monocytogenes | 1 | 2011 | 102 | 0.020 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2013 | 571 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2015 | 2524 | 0.020 |
Why?
|
| Nucleic Acid Hybridization | 1 | 1989 | 187 | 0.020 |
Why?
|
| Postoperative Period | 1 | 2010 | 351 | 0.020 |
Why?
|
| Arthritis, Experimental | 1 | 1990 | 136 | 0.020 |
Why?
|
| MAP Kinase Signaling System | 1 | 2011 | 307 | 0.020 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2011 | 231 | 0.020 |
Why?
|
| Biological Evolution | 1 | 2012 | 466 | 0.020 |
Why?
|
| Emergency Service, Hospital | 1 | 2021 | 2377 | 0.020 |
Why?
|
| Resuscitation | 1 | 1991 | 310 | 0.020 |
Why?
|
| Abortion, Habitual | 1 | 1988 | 4 | 0.020 |
Why?
|
| Host vs Graft Reaction | 1 | 1988 | 2 | 0.020 |
Why?
|
| Helium | 1 | 2007 | 6 | 0.020 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2009 | 267 | 0.020 |
Why?
|
| Calcium Phosphates | 1 | 2007 | 28 | 0.020 |
Why?
|
| Databases, Genetic | 1 | 2009 | 238 | 0.020 |
Why?
|
| Platelet Count | 1 | 2007 | 94 | 0.020 |
Why?
|
| Particle Size | 1 | 2009 | 381 | 0.020 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 1990 | 407 | 0.020 |
Why?
|
| Hydrogen Peroxide | 1 | 2009 | 335 | 0.020 |
Why?
|
| Fluoroscopy | 1 | 2007 | 179 | 0.020 |
Why?
|
| Infertility, Female | 1 | 1988 | 121 | 0.020 |
Why?
|
| Blood Flow Velocity | 1 | 2007 | 420 | 0.010 |
Why?
|
| Imines | 1 | 2005 | 6 | 0.010 |
Why?
|
| Alcohol Dehydrogenase | 1 | 2005 | 16 | 0.010 |
Why?
|
| Psychometrics | 1 | 1989 | 731 | 0.010 |
Why?
|
| Regional Blood Flow | 1 | 2007 | 514 | 0.010 |
Why?
|
| Publishing | 1 | 2006 | 114 | 0.010 |
Why?
|
| Cephalosporin Resistance | 1 | 2005 | 1 | 0.010 |
Why?
|
| Cefotaxime | 1 | 2005 | 3 | 0.010 |
Why?
|
| Ceftazidime | 1 | 2005 | 7 | 0.010 |
Why?
|
| Interleukin-1 Receptor-Associated Kinases | 1 | 2005 | 41 | 0.010 |
Why?
|
| PC12 Cells | 1 | 2005 | 42 | 0.010 |
Why?
|
| Isoproterenol | 1 | 2005 | 96 | 0.010 |
Why?
|
| Adrenergic beta-Agonists | 1 | 2005 | 92 | 0.010 |
Why?
|
| Histidine | 1 | 2005 | 66 | 0.010 |
Why?
|
| Cardiovascular Diseases | 1 | 2017 | 2183 | 0.010 |
Why?
|
| Laboratories | 1 | 2005 | 110 | 0.010 |
Why?
|
| Bronchodilator Agents | 1 | 2005 | 187 | 0.010 |
Why?
|
| Periodicals as Topic | 1 | 2006 | 209 | 0.010 |
Why?
|
| Data Collection | 1 | 2006 | 639 | 0.010 |
Why?
|
| Pseudogenes | 1 | 2003 | 20 | 0.010 |
Why?
|
| Genes, Protozoan | 1 | 2003 | 13 | 0.010 |
Why?
|
| Injections, Subcutaneous | 1 | 2004 | 170 | 0.010 |
Why?
|
| Aging | 1 | 2014 | 1962 | 0.010 |
Why?
|
| Gene Duplication | 1 | 2003 | 66 | 0.010 |
Why?
|
| Arginine | 1 | 2005 | 264 | 0.010 |
Why?
|
| CD3 Complex | 1 | 2003 | 112 | 0.010 |
Why?
|
| Kuwait | 1 | 2002 | 1 | 0.010 |
Why?
|
| CD4 Antigens | 1 | 2003 | 137 | 0.010 |
Why?
|
| Microbiological Techniques | 1 | 2003 | 30 | 0.010 |
Why?
|
| Peptides | 1 | 2009 | 997 | 0.010 |
Why?
|
| Chemotaxis | 1 | 2003 | 122 | 0.010 |
Why?
|
| Bromodeoxyuridine | 1 | 2002 | 77 | 0.010 |
Why?
|
| Cause of Death | 1 | 2005 | 470 | 0.010 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2003 | 33 | 0.010 |
Why?
|
| Anaplasia | 1 | 2001 | 7 | 0.010 |
Why?
|
| Sibling Relations | 1 | 2001 | 10 | 0.010 |
Why?
|
| Bipolar Disorder | 1 | 2005 | 275 | 0.010 |
Why?
|
| Fires | 1 | 2002 | 77 | 0.010 |
Why?
|
| Microelectrodes | 1 | 2001 | 49 | 0.010 |
Why?
|
| Genetic Complementation Test | 1 | 2001 | 72 | 0.010 |
Why?
|
| Lymphocyte Antigen 96 | 1 | 2001 | 23 | 0.010 |
Why?
|
| Calcium | 1 | 2007 | 1189 | 0.010 |
Why?
|
| Chromosome Aberrations | 1 | 2001 | 165 | 0.010 |
Why?
|
| Clone Cells | 1 | 2001 | 263 | 0.010 |
Why?
|
| Fatal Outcome | 1 | 2001 | 305 | 0.010 |
Why?
|
| Nuclear Family | 1 | 2001 | 50 | 0.010 |
Why?
|
| Histocompatibility Testing | 1 | 2001 | 123 | 0.010 |
Why?
|
| Internet | 1 | 2005 | 689 | 0.010 |
Why?
|
| Sodium Dodecyl Sulfate | 1 | 2000 | 25 | 0.010 |
Why?
|
| Functional Laterality | 1 | 2001 | 240 | 0.010 |
Why?
|
| Acoustic Stimulation | 1 | 2001 | 333 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2000 | 331 | 0.010 |
Why?
|
| Cell Membrane | 1 | 2003 | 707 | 0.010 |
Why?
|
| Reaction Time | 1 | 2001 | 431 | 0.010 |
Why?
|
| Respiratory Tract Infections | 1 | 2004 | 394 | 0.010 |
Why?
|
| Plasmids | 1 | 2000 | 373 | 0.010 |
Why?
|
| Comorbidity | 1 | 2004 | 1657 | 0.010 |
Why?
|
| Propranolol | 1 | 1998 | 44 | 0.010 |
Why?
|
| Brain Mapping | 1 | 2001 | 534 | 0.010 |
Why?
|
| Electrocardiography, Ambulatory | 1 | 1998 | 63 | 0.010 |
Why?
|
| Tachycardia, Supraventricular | 1 | 1998 | 49 | 0.010 |
Why?
|
| Attention | 1 | 2001 | 461 | 0.010 |
Why?
|
| Radiography, Thoracic | 1 | 1998 | 172 | 0.010 |
Why?
|
| Lung Volume Measurements | 1 | 1997 | 46 | 0.010 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 1998 | 252 | 0.010 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2003 | 1138 | 0.010 |
Why?
|
| Organ Size | 1 | 1997 | 459 | 0.010 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 1996 | 94 | 0.010 |
Why?
|
| Rabbits | 1 | 1996 | 652 | 0.010 |
Why?
|
| Proteus | 1 | 1993 | 5 | 0.010 |
Why?
|
| Pseudomonas | 1 | 1993 | 30 | 0.010 |
Why?
|
| Colony Count, Microbial | 1 | 1993 | 89 | 0.010 |
Why?
|
| Chemistry | 1 | 1990 | 40 | 0.010 |
Why?
|
| Chemical Phenomena | 1 | 1990 | 77 | 0.010 |
Why?
|
| Rats, Inbred Lew | 1 | 1990 | 104 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 1993 | 1300 | 0.000 |
Why?
|
| Administration, Oral | 1 | 1993 | 862 | 0.000 |
Why?
|
| Drug Therapy, Combination | 1 | 1993 | 1043 | 0.000 |
Why?
|
| Organometallic Compounds | 1 | 1990 | 113 | 0.000 |
Why?
|
| Structure-Activity Relationship | 1 | 1990 | 563 | 0.000 |
Why?
|
| Molecular Structure | 1 | 1990 | 486 | 0.000 |
Why?
|
| Histocompatibility | 1 | 1988 | 20 | 0.000 |
Why?
|